

RESEARCH ARTICLE

Evaluation and comparison of covariate balance metrics in studies with time-dependent confounding

David Adenyo^{1,2} | Jason R. Guertin^{1,2} | Bernard Candas¹ | Caroline Sirois^{2,3} | Denis Talbot^{1,2}

¹Département de médecine sociale et préventive, Université Laval, Québec, Canada

²Centre de recherche du CHU de Québec, Université Laval, Québec, Canada

³Faculté de pharmacie, Université Laval, Québec, Canada

Correspondence

Denis Talbot, Département de médecine sociale et préventive, Université Laval.

Email: denis.talbot@fmed.ulaval.ca

Abstract

Marginal structural models have been increasingly used by analysts in recent years to account for confounding bias in studies with time-varying treatments. The parameters of these models are often estimated using inverse probability of treatment weighting. To ensure that the estimated weights adequately control confounding, it is possible to check for residual imbalance between treatment groups in the weighted data. Several balance metrics have been developed and compared in the cross-sectional case but have not yet been evaluated and compared in longitudinal studies with time-varying treatment. We have first extended the definition of several balance metrics to the case of a time-varying treatment, with or without censoring. We then compared the performance of these balance metrics in a simulation study by assessing the strength of the association between their estimated level of imbalance and bias. We found that the Mahalanobis balance performed best. Finally, the method was illustrated for estimating the cumulative effect of statins exposure over one year on the risk of cardiovascular disease or death in people aged 65 and over in population-wide administrative data. This illustration confirms the feasibility of employing our proposed metrics in large databases with multiple time-points.

KEY WORDS

covariate balance, time-dependent confounding, inverse probability of treatment weighting, balance metric, time-varying covariates

1 | INTRODUCTION

Marginal structural models (MSMs) are an increasingly popular approach for estimating the effect of a time-varying treatment or exposure using observational data^{1,2}. Unlike traditional approaches, such as propensity score matching or covariate adjustment in an outcome model, MSMs can appropriately deal with covariates that are both confounders for the effect of a treatment at a given time-point and intermediate variables in the causal pathway between a previous treatment and the outcome^{1,2}. The most common approach for estimating the parameters of an MSM is to adjust for measured confounders with an inverse probability of treatment weighting (IPTW) estimator^{1,2}. When using this approach, each individual is assigned a weight that corresponds to the inverse of the probability of their observed treatment at each time-point, conditional on their past treatment and covariate history. Intuitively, IPTW creates a pseudo-population where the treatment at each time-point is independent of previously measured confounders, thus mimicking a sequential randomized trial with respect to these confounders^{1,2}.

One condition to obtain valid causal effect estimates when using this IPTW estimator is the absence of residual systematic differences in the observed baseline and time-varying covariates between treatment groups in the weighted data^{3,4}. In settings where the effect of a treatment at a single time-point is of interest, various methods, or metrics, have been proposed to assess if treatment groups are balanced. Notably, several authors have developed methods for evaluating imbalance on one covariate at a time in the weighted sample, including the standardized mean difference (SMD), the Kolmogorov-Smirnov (KS) test statistic and graphical comparisons of the distribution of continuous variables^{5,6,7}. In addition, other methods such as the Lévy distance

(LD) and the non-parametric overlap coefficient (OVL) have been developed in the context of matching on the propensity score⁷. Various other metrics have also been developed to assess the balance on several covariates simultaneously, including the Mahalanobis balance (MHB)^{7,8}, the C-statistic of the propensity score model^{7,9}, the L_1 balance metric or the L_1 median^{7,10}. One potential advantage of such global metrics is their ability to take into account the correlations between the covariates and to assess how the joint distribution of the covariates is imbalanced between treatment groups. Recently *Franklin et al*⁷ proposed two new measures in addition to the previous metrics in the context of matching on the propensity score, namely the post-matching C-statistic as well as the general weighted difference (GWD). Using a simulation study, *Franklin et al*⁷ compared the performance of various metrics when using a matching estimator and concluded that the post-matching C-statistic, SMD, and GWD performed best with regard to their association with bias.

Although there have been significant methodological developments regarding balance checking methods, there are still important gaps in knowledge, specifically in the longitudinal-MSM setting. For example, while *Franklin et al*⁷ have indicated how each of the above-mentioned metrics are calculated when adjusting for confounders using an IPTW estimator, the performance of the metrics was not compared in their simulation study when using this estimator. In addition, prior research mainly focused on balance metrics for a treatment measured at a single time-point. Recently, the SMD metric has been adapted to the time-varying treatment setting^{3,11}. To the best of our knowledge, the other metrics have not yet been extended to this longitudinal setting and their relative performance has not been examined in simulation studies.

The objective of this study is to evaluate and compare various metrics in the context of MSMs using IPTW in order to determine which metrics are most associated with bias in the estimation of the effect of a time-varying treatment. This paper is structured as follows. In Section 2, we first introduce the notation as well as the concepts underlying MSMs. We first present the case without censoring (e.g., loss-to-follow up) and subsequently extend the notation to the case with censoring. Then, we define the metrics to evaluate covariate balance in a longitudinal weighted sample. Section 3 presents a Monte Carlo simulation study that evaluates and compares the balance metrics discussed above in the context of an MSM. In Section 4, we present an application to real-world data in which we study the effect of statin use for the primary prevention of cardiovascular disease among older adults. The paper concludes in Section 5 with a discussion.

2 | METHODS

2.1 | Notation and marginal structural models for uncensored data

We first present the notation for marginal structural models for uncensored data. Consider a study with $T+1$ follow-up times and n individuals sampled from a population so that the time-ordered data take the following form $\mathcal{O}_i = \{X_{i0}, A_{i0}, X_{i1}, A_{i1}, \dots, X_{iT}, A_{iT}, Y_i\}$ where A_{it} represents the treatment (or exposure) variable of individual i ($i = 1, 2, \dots, n$) at time t ($t = 0, 1, \dots, T$), X_{it} is a vector containing the time-dependent confounders, and Y_i is the outcome at the end of the study at time $T+1$. To simplify the presentation, we assume that A_{it} is a binary variable where $A_{it} = 1$ ($A_{it} = 0$) indicates that individual i is treated (untreated) at time t , but the extension to the case of a multilevel exposure is straightforward. At each time t , we admit that X_{it} is realized before A_{it} and is thus not affected by A_{it} . Let $\bar{A}_{it} = \{A_{i0}, A_{i1}, \dots, A_{it}\}$ and $\bar{X}_{it} = \{X_{i0}, X_{i1}, \dots, X_{it}\}$ denote the history of treatment and covariates up to time t for individual i , respectively. We denote by $Y_i^{\bar{a}_T}$, the counterfactual outcome for individual i under the full treatment history $\bar{A}_{iT} = \bar{a}_T$.

The problem of estimating the effect of the treatment history can be expressed in a general way as the estimation of the parameters of a model for the counterfactual outcome expectation according to the treatment history. The following expression for an MSM is obtained: $E[Y^{\bar{a}_T}] = g(\beta, \bar{a}_T)$ where β is a vector of parameters that captures the causal effect of the treatment history on the outcome and g is a function defined by the analyst.

The nonparametric identification of the parameters of an MSM from the observed data can be achieved under four key assumptions: i) consistency, which requires that, for any individual, if $\bar{A}_T = \bar{a}_T$, then $Y = Y^{\bar{a}_T}$; ii) sequential exchangeability, which requires that the treatment at each time-point is not confounded by unobserved factors, i.e., $Y^{\bar{a}_T} \perp\!\!\!\perp A_t | \bar{A}_{t-1}, \bar{X}_t$; iii) positivity, which requires $0 < P(A_t = 1 | \bar{A}_{t-1} = \bar{a}_{t-1}, \bar{X}_t = \bar{x}_t) < 1$ at every time-point t for a given treatment history \bar{a}_{t-1} and covariate history \bar{x}_t ; iv) a unique and stable treatment value: there is no interference between subjects and there is only one version of each treatment level^{12,13}.

The most common approach for estimating the parameters of an MSM is to use an IPTW estimator, where each individual is assigned a weight that corresponds to the product of the inverse of their probability of receiving the treatment they received at

each time-point:

$$U_i = \prod_{t=0}^T \frac{1}{P(A_t = a_{it} | \bar{A}_{t-1} = \bar{a}_{i,t-1}, \bar{X}_t = \bar{x}_{it})}. \quad (1)$$

As mentioned in the introduction, the IPTW creates a pseudo-population where the treatment at each time-point is independent of previously measured confounders^{1,2}. However, individuals receiving an unusual treatment at a time-point conditional on their past can have extreme weights. This may increase the variance of the treatment effect estimator. To overcome this problem, it has been suggested to use stabilized weights instead of using standard weights. Stabilized weights are defined as:

$$SW_i = \prod_{t=0}^T \frac{P(A_t = a_{it} | \bar{A}_{t-1} = \bar{a}_{i,t-1})}{P(A_t = a_{it} | \bar{A}_{t-1} = \bar{a}_{i,t-1}, \bar{X}_t = \bar{x}_{it})}. \quad (2)$$

Robins¹ has shown that these stabilized weights are optimal from a variance perspective. However, they do not balance the treatment groups according to prior treatments, and only balance prior covariates conditionally on previous treatment history³. In other words, when checking balance in data weighted according to these stabilized weights, one would need to compare each treatment group at each time-point for each possible treatment history, that is $A_t \prod \bar{X}_{t-1} | \bar{A}_{t-1} = \bar{a}_{t-1}$ for all $t = 1, \dots, T$ and all \bar{a}_{t-1} . In situations with multiple time-points, the number of balance check to make may become unmanageable. Previous approaches for checking balance in a longitudinal setting are affected by this challenge³. As such, we recommend not using these stabilized weights to check balance. Another form of stabilized weights, the marginal stabilized weights¹⁴, could instead be considered:

$$W_i = \prod_{t=0}^T \frac{P(A_t = a_{it})}{P(A_t = a_{it} | \bar{A}_{t-1} = \bar{a}_{i,t-1}, \bar{X}_t = \bar{x}_{it})}. \quad (3)$$

These weights are expected to have a lower variance than the unstabilized weights and are theoretically expected to balance treatment groups at each time-point according to both prior treatment and prior covariates, unconditionally on previous treatment history. In other words, one only needs to verify if $A_t \prod \bar{X}_{t-1}$ for all $t = 1, \dots, T$ in the weighted data according to these weights.

Various methods can be used for estimating the conditional probabilities involved in the weights (1), (2), (3), including parametric methods, in particular logistic regression^{15,16}, or non-parametric and machine learning methods such as neural networks, classification/regression trees^{17,18,19} as well as ensemble methods such as Super Learner²⁰. However, using non-parametric approaches is fraught with challenges and does not always improve the validity above parametric methods^{21,22}. In the following, we focus on marginal stabilized weights and logistic regression for simplicity.

2.2 | Notation and marginal structural models for censored data

The notation we have just presented can be extended to the case of censored data, that is, for data where the follow-up is incomplete for some subjects. Such censoring is very common in longitudinal studies. Ignoring these losses to follow-up may induce selection bias. It is possible to adjust for such selection bias when using MSMs by employing inverse probability of censoring weights²³. More precisely, denote by $\bar{C}_{it} = \{C_{i0}, C_{i1}, \dots, C_{it}\}$ the right censoring history for subject i up to time t , where C_{it} is the variable corresponding to the loss to follow-up status at time t for subject i with $C_t = 1$ if the subject is lost to follow-up (censored) and $C_t = 0$ otherwise. We assume that once a subject becomes censored, they do not re-enter the study in the future (if $C_t = 0$, then $C_k = 0$ for all $k > t$). In this case, the time-ordered data take the following form $\mathcal{O}_i = \{C_{i0}, X_{i0}, A_{i0}, C_{i1}, X_{i1}, A_{i1}, \dots, C_{iT}, X_{iT}, A_{iT}, Y_i\}$.

The problem of interest then becomes the estimation of the counterfactual outcome expectation under treatment history \bar{a}_T and under no censoring $\bar{c}_T = 0$. The MSM can be expressed in a general way as $E[Y^{\bar{a}_T, \bar{c}_T=0}] = g(\beta, \bar{a}_T)$. The identification of the parameters of this MSM can be achieved under similar assumptions as those that were presented in the previous section, by considering C_t as a second time-varying treatment. More precisely, the identification requires the sequential exchangeability for A_t and C_t , that is, $Y^{(\bar{a}_T, \bar{c}_T=0)} \prod A_t | \bar{A}_{t-1}, \bar{C}_t = 0, \bar{X}_t$ and $Y^{(\bar{a}_T, \bar{c}_T=0)} \prod C_t | \bar{A}_{t-1}, \bar{C}_{t-1} = 0, \bar{X}_{t-1}$; the joint positivity for (A_t, C_t) , that is, $0 < P(A_t = 1 | \bar{A}_{t-1} = \bar{a}_{t-1}, \bar{X}_t = \bar{x}_t, \bar{C}_t = 0) < 1$ and $0 < P(C_t = 0 | \bar{A}_{t-1} = \bar{a}_{t-1}, \bar{X}_{t-1} = \bar{x}_{t-1}, \bar{C}_{t-1} = 0)$; and consistency.

The marginal stabilized inverse probability of censoring weights (IPCW) W_i^C are constructed similarly to the IPTW by modeling the probability of not being lost to follow-up:

$$W_i^C = \prod_{t=0}^T \frac{P(C_t = 0 | \bar{C}_{t-1} = 0)}{P(C_t = 0 | \bar{A}_{t-1} = a_{it,t-1}, \bar{X}_{t-1} = \bar{x}_{it,t-1}, \bar{C}_{t-1} = 0)}. \quad (4)$$

The IPTW also needs to be modified to account for the fact that it cannot be computed for subjects that are censored:

$$W_i^A = \prod_{t=0}^T \frac{P(A_t = a_{it} | \bar{C}_t = 0)}{P(A_t = a_{it} | \bar{A}_{t-1} = \bar{a}_{it,t-1}, \bar{X}_t = \bar{x}_{it}, \bar{C}_t = 0)}. \quad (5)$$

Under the previous identifiability assumptions, the parameters of the MSM can be estimated by fitting a model $E[Y | \bar{A}, \bar{C}_T = 0] = g(\beta, \bar{A})$ weighting by the product of the IPTW and the IPCW. We denote this product by $W^{A,C}$. These weights control for both confounding and selection biases by mimicking a sequential randomized trial without censoring relative to measured covariates.

2.3 | Balance metrics

In this section, we extend the definition of several balance metrics to the time-varying treatment without censoring and with censoring setting. We considered eight of the ten metrics that were defined in *Franklin et al*⁷ for the case of a treatment and covariates measured at a single time-point. We did not retain the L_1 metrics (L_1 measure and L_1 median) because of their inferior performance in previous simulations⁷. The first five metrics we present below evaluate the balance on a single covariate at a time and the last three evaluate the balance on several covariates simultaneously.

Recall that the covariates must be chosen to satisfy the sequential exchangeability assumption to yield consistent estimators. In the time-varying treatment without censoring setting, treatment groups at each time-point should be balanced relative to previous covariates in data weighted according to W , that is $A_t \perp\!\!\!\perp \bar{X}_t$ for all $t = 0, \dots, T$. To verify this balancing property, we propose to compare the distribution between treatment groups at each time-point $t = 1, \dots, T$ of each previous covariate X_{t-k} for $k = 0, \dots, t$ when considering metrics that apply to a single covariate at a time. When considering metrics that can consider multiple covariates simultaneously, we propose to consider jointly all covariates that are measured at a given time-point, but to consider separately the covariates that are measured at different time-points. In other words, we propose comparing the joint distribution between treatment groups at each time-point $t = 0, \dots, T$ of all the covariates X_{t-k} , separately for all $k = 0, \dots, t$. This choice avoids considering simultaneously the repeated version of the same variables X_{t-k} and X_{t-k-1} , which may lead to collinearity issues. To simplify the presentation, we define the metrics considering the marginal stabilized weights W .

1. The *absolute difference* is defined as the absolute value of the difference in the means of a given covariate between the treatment groups. This metric as well as standardized means difference have recently been developed in the longitudinal setting by *Jackson et al*³. Unlike these authors, we propose using products up to time T instead of up to time t in Equations (1), (2), (3), (4) and (5) to check the balance at time t . We believe the choice of using the weights with all product terms is preferable since the parameters of the MSM are actually estimated using these weights, not with the partial products. As such, we define the absolute difference for covariate X_{t-k} between treatment groups at time t as $D_{t,k} = |E[W \times I(A_t = 1) \times X_{t-k}] - E[W \times I(A_t = 0) \times X_{t-k}]|$, where $0 \leq k \leq t$.
2. The *standardized means difference* is the absolute difference divided by the the pooled standard deviation of the covariate between treatment groups $SMD_{t,k} = D_{t,k} / \sqrt{(s_{1,t,k}^2 + s_{0,t,k}^2) / 2}$, where $s_{1,t,k}^2$ and $s_{0,t,k}^2$ are the estimated weighted variances in the treated ($A = 1$) and untreated ($A = 0$) groups respectively, $0 \leq k \leq t$. The threshold usually chosen to define the existence of a residual imbalance is 0.1 (10%)^{9,16}.
3. The *overlap coefficient* is defined as the proportion of overlap in two density functions, calculated by finding the area under the minimum of the two curves (treated and untreated). For a binary variable, the OVL quantifies the overlap in probability densities between the two groups of treated and untreated subjects⁶. However, for a continuous variable, the OVL is estimated by the non-parametric kernel density estimation method^{6,24}. In this paper, we calculated the OVL for a continuous variable in a general way as follows : $OVL_{t,k} = \int \min_{x_{t-k}} (\hat{f}_{W \times I(A_t=1) \times X_{t-k}}(x_{t-k}), \hat{f}_{W \times I(A_t=0) \times X_{t-k}}(x_{t-k})) dx_{t-k}$ where $0 \leq k \leq t$ and $\hat{f}_{W \times I(A_t=J) \times X_{t-k}}(x_{t-k})$ is the weighted density function of the covariate in the treatment group J . The OVL varies between 0 (no overlap) and 1 (optimal balance) and its value is independent of the unit of measurement^{7,25}.

4. The *Kolmogorov-Smirnov* distance is defined as the maximum vertical distance of the cumulative distribution functions between the groups of treatments. In weighted data, its expression is given by $KS_{t,k} = \max_{x_{t-k}} |\hat{F}_{W \times I(A_t=1) \times X_{t-k}}(x_{t-k}) - \hat{F}_{W \times I(A_t=0) \times X_{t-k}}(x_{t-k})|$, where $\hat{F}_{W \times I(A_t=1) \times X_{t-k}}(x_{t-k})$ and $\hat{F}_{W \times I(A_t=0) \times X_{t-k}}(x_{t-k})$ denote the weighted empirical cumulative distribution function in the treated and untreated groups, respectively, where $0 \leq k \leq t$. This metric ranges from 0 (optimal balance) to 1^{7,25}.
5. The *Lévy distance* is defined as the length of the side of the largest square that can fit between two cumulative distribution weighted functions: $LV_{t,k} = \min\{\epsilon > 0 : \hat{F}_{W \times I(A_t=0) \times X_{t-k}}(x_{t-k} - \epsilon) - \epsilon \leq \hat{F}_{W \times I(A_t=1) \times X_{t-k}}(x_{t-k} - \epsilon) \leq \hat{F}_{W \times I(A_t=0) \times X_{t-k}}(x_{t-k} + \epsilon) + \epsilon, \forall x_{t-k}\}$, where $0 \leq k \leq t$. Similarly, the Lévy distance varies from 0 to 1, where the value 0 indicates optimal balance^{7,25}.
6. We propose a new version of the *Mahalanobis balance*. Unlike *Franklin et al*⁷, we consider the pooled variance-covariance matrix of covariates in the definition of the MHB instead of the sample variance-covariance matrix of covariates. We made this choice for two reasons. Firstly, it reinforces the concordance between MHB and SMD, since MHB is simply the matrix version of SMD. Secondly, it offers the possibility of proposing a threshold for MHB since, unlike SMD, there is no established acceptable limit. Based on these connections, we propose to use $p \times 0.01$ as a threshold, where p is the number of covariates (see Appendix 3 in the Supporting information). It is defined as $MHB_{t,k} = (\bar{X}_1 - \bar{X}_0)^T \Sigma^{-1} (\bar{X}_1 - \bar{X}_0)$, where $\bar{X}_j = E[W \times I(A_t = j) \times \mathbf{X}_{t-k}]$ is the vector of weighted means of the covariates in treatment group j , and Σ is the pooled within-group variance-covariance matrix of the covariates, with $0 \leq k \leq t$.
7. We also define the *post-weighting C-statistic (CS)*. It is given by the area under the receiver operating characteristic (ROC) curve which measures the ability of model estimated in the weighted sample to discriminate treated subjects from untreated subjects. Its value varies between 0.5 (inability of the Propensity score (PS) model to discriminate treated subjects from untreated subjects after weighting) and 1 (the worst balance after weighting)⁷.
8. The *general weighted difference* is given by $GWD_{t,k} = \sum_{0 \leq a \leq b \leq C} w_{ab} |E[W \times I(A_t = 1) \times X_{a,t-k} X_{b,t-k}] - E[W \times I(A_t = 0) \times X_{a,t-k} X_{b,t-k}]|$, where C is the number of measured covariates, X_0 is a unit vector and w_{ab} is a weight assigned to the pair of covariates $X_a X_b$, where $w_{ab} = 1/s_{ab}$ if $a = 0$ and $w_{ab} = 0.5/s_{ab}$ otherwise, s_{ab} the pooled intra-group standard deviation of $X_{a,t-k} X_{b,t-k}$, $0 \leq k \leq t$.

In the time-varying treatment with censoring setting, treatment groups at each time-point should be balanced relative to previous covariates among persons who have not been censored in data weighted according to $W^{A,C}$, that is $A_t \prod \bar{X}_t, \bar{C}_t = 0$ for all $t = 0, \dots, T$. For example for the absolute difference we have: $D_{t,k} = |E[W^{A,C} \times I(A_t = 1) \times X_{t-k}, \bar{C}_{t-k} = 0] - E[W^{A,C} \times I(A_t = 0) \times X_{t-k}, \bar{C}_{t-k} = 0]|$, where $0 \leq k \leq t$. The definitions are analogous when considering the others metrics. The R code for implementing all balance metrics is available on Github (<https://github.com/detal9/LongitudinalBalanceMetrics>).

3 | SIMULATIONS

We now present the simulation study we conducted to evaluate and compare the performance of the balance metrics we presented in the previous section. We first provide a general overview of the simulation study before presenting the data-generating equations in Subsection 3.2.

3.1 | General presentation of the simulation study

Among the simulation scenarios we considered, seven were adapted from *Franklin et al*⁷, and three are new scenarios. These scenarios differ regarding the type of relations between covariates and treatments (linear or nonlinear), the type of relations between covariates and outcome (linear or nonlinear), the sample size ($n = 10,000$ or $n = 1,000$) and the strength of the relations between the variables (see Section 3.2 and 3.3 for more details). We first elaborated the scenarios in the case of uncensored data and subsequently for censored data. To simplify the simulation study, all scenarios feature two time-points where covariates and treatment are measured, and the outcome is measured at a third time-point.

For each scenario in the time-varying treatment without censoring setting, a vector of six time-varying covariates $X_t = (L_t, M_t, N_t, O_t, P_t, Q_t)$, $t = 0, 1$ and a binary time-varying treatment variable were generated (Figure 1). The variables L_t, M_t, N_t were continuous, more precisely L_t and N_t were normally distributed and M_t was a lognormal variable. We simulated O_t and

P_t as binomial variables and specified that O_t was strongly correlated with L_t in all scenarios. Finally, Q_t was simulated as an ordered categorical variable. Transformation of these variables were also considered to create non-linear relations ($T_t = \sin(L_t)$, $R_t = M_t^2$, $V_t = N_t \times O_t$, $Z_t = O_t \times P_t$). Inspired by our application of interest, we generated data on Y such that treatment at each time-point reduces the risk of the outcome while higher covariate values increase the risk of outcome. The MSM of interest was $\text{logit}(E[Y^{\bar{a}_1}]) = \beta_0 + \beta_1 a_0 + \beta_2 a_1$ and the true values of its parameters were estimated by Monte Carlo simulation of the counterfactual outcomes with a sample size of $n = 100,000$ (see <https://github.com/detal9/LongitudinalBalanceMetrics> for the source R code).

For each simulation scenario, we generated 1,000 datasets of size n . For each dataset, we estimated the treatment probabilities $P(A_t | \bar{A}_{t-1}, \bar{X}_t)$ and $P(A_t)$ for $t = 0, 1$ using logistic regression models, either including the independent variables as main terms only (simple specification), or including both main terms and two-way interactions between the variables (complex specification). Using the predicted probabilities from these models, we computed five different types of weights based on $W_0 = \frac{P(A_0)}{P(A_0 | X_0)}$ and $W_1 = \frac{P(A_1)}{P(A_1 | A_0, X_0, X_1)}$ in order to produce datasets with varying levels of balance and bias. For the first weight, we considered $W_0 \times W_1$, for the second weight we considered only W_1 , for the third weight we considered only W_0 , for the fourth weight we considered the product of W_0 truncated at the 90th percentiles with W_1 and finally we considered the product of W_0 with W_1 truncated at the 90th percentiles. We then computed each balance metric at all time-points and either for each covariates separately (D, SMD, OVL, KS, LD) or for all covariates globally (MHB, CS, GWD) in the unweighted data and in data weighted according to each of the five aforementioned weights. To calculate the CS, we re-estimated in the weighted data the propensity score at each time-point without conditioning on previous treatment to measure the ability of the covariates to distinguish between treated and untreated patients after weighting. We also estimated the bias in each of the dataset for each of the parameters of the MSM by computing the difference between the estimated odds ratio using the IPTW estimator and the true odds ratio. The bias of the crude (unweighted) model was also estimated. For metrics that measure the balance of only one covariate at a time (D, SMD, OVL, KS, and LD), we calculated the metric for each covariate at each time-point and then averaged the values over covariates, resulting in three average balance variables: average balance between A_0 groups according to covariates X_0 , average balance between A_1 groups according to covariates X_0 , and average balance between A_1 groups according to covariates X_1 . As will be seen shortly, these averages were used to evaluate the performance of the balance metrics. For metrics that measure the balance for multiple covariates at a time, we also obtained three analogous balance variables since we considered jointly all variables measured at a given time-point, but considered separately variables measured at different time-points. To make the balance metrics comparable, we transformed the balance metrics so that 0 indicates perfect balance and higher values indicate larger imbalances. In particular, for the *OVL* we calculated $1 - OVL$ and for *C* we calculated $2 \times (C - 0.5)$.

To evaluate the performance of the eight balance metrics mentioned in Section 2.3, we first created, for each balance metric, a dataset with 6,000 rows (obtained by considering the 1,000 simulated datasets of each of the unweighted and five types of weights) and four columns representing the estimated bias and the average balance variables. We then fitted a separate linear regression model for each metric on these data where the dependent variable was the estimated bias and the independent variables were the balance variables, featuring both linear and quadratic terms for each independent variable. For each estimated model, we extracted the proportion of variation explained (R^2). We also extracted the estimated intercept (β_0) of each model, which measures the average bias in absence of imbalance in the explored scenario. As in *Franklin et al*⁷, we focus the interpretation around the comparison of relative R^2 across metrics, noting that the R^2 themselves are not very informative since they are highly dependent on the simulation scenarios.

We repeated the analyses as in the previous paragraphs in the time-varying treatment with censoring setting (only for the base case and for simple propensity score) by simulating binary censoring indicators C_t where $C_t = 1$ censored and $C_t = 0$ otherwise such that 20% of individuals were censored at time $t = 1$. In such case we replaced W_0 and W_1 by $W_0^{A,C} = \frac{P(A_0 | C_0=0)}{P(A_0 | X_0, C_0=0)}$ and $W_1^{A,C} = \frac{P(A_1 | \bar{C}_1=0)}{P(A_1 | A_0, X_0, X_1, \bar{C}_1=0)} \times \frac{P(C_1 | C_0=0)}{P(C_1 | A_0, X_0, C_0=0)}$ respectively.

3.2 | Data-generating equations

We now present the specific data-generating equations that we used. For each simulation scenario, n independent observations were generated according to these equations. To simplify the presentation, we present the data-generating equations in a general framework where steps 2, 3, 5, 6, and 7 correspond to the case of uncensored data and steps 1 – 7 correspond to the case of data with censoring.

1. Censoring indicator at time-point 0: $C_0 = 0$ for all subjects




FIGURE 1 Causal Directed Acyclic Graphs describing measured covariates X_t , exposures A_t , outcome Y and parameters of the data-generating mechanism for an observational study where exposure is (a) not censored (b) censored, with continuing data collection among the uncensored at time t i.e. $C_t = 0$.

2. Covariates at time-point 0: $L_0 \sim N(0, 1)$, $M_0 \sim \log N(0, 1)$, $N_0 \sim N(0, 10)$, $O_0 \sim \text{Bern}(p = \text{expit}(\delta_0 + 2L_0))$, $P_0 \sim \text{Bern}(p = 0.2)$, Q_0 was simulated as an ordered categorical variable with prevalences of 50%, 30%, 10%, 5%, and 5% in categories 1 to 5, respectively, $T_0 = \sin(L_0)$, $R_0 = M_0^2$, $V_0 = N_0 \times O_0$, $Z_0 = O_0 \times P_0$
3. Exposure at time-point 0: $A_0 \sim \text{Bern}(p_{A_0} = \text{expit}(\alpha_0 + \phi_{L_0}L_0 + \phi_{M_0}M_0 + \phi_{N_0}N_0 + \phi_{O_0}O_0 + \phi_{P_0}P_0 + \phi_{Q_0}Q_0 + \phi_{T_0}T_0 + \phi_{R_0}R_0 + \phi_{V_0}V_0 + \phi_{Z_0}Z_0))$
4. Censoring indicator at time-point 1: $C_1 \sim \text{Bern}(p_{C_1} = \text{expit}(\mu_1 + \mu_{L_0}L_0 + \mu_{M_0}M_0 + \mu_{N_0}N_0 + \mu_{O_0}O_0 + \mu_{P_0}P_0 + \mu_{Q_0}Q_0 + \lambda A_0))$
5. Covariates at time-point 1: $L_1 \sim N(\beta L_0 + \gamma_0 A_0, 1)$, $M_1 \sim \log N(\beta M_0 + \gamma_1 A_0, 1)$, $N_1 \sim N(\beta N_0 + \gamma_2 A_0, 10)$, $O_1 \sim \text{Bern}(p = \text{expit}(\delta_1 + \beta O_0 + 2L_1 + \gamma_3 A_0))$, $P_1 \sim \text{Binary}(p = \text{expit}(\mu_0 + \beta P_0 + \gamma_4 A_0))$, Q_1 was simulated as an ordered categorical variable with prevalences of 40%, 30%, 20%, 5%, and 5% in categories 1 to 5, $T_1 = \sin(L_1)$, $R_1 = M_1^2$, $V_1 = N_1 \times O_1$, $Z_1 = O_1 \times P_1$
6. Exposure at time-point 1: $A_1 \sim \text{Bern}(p_{A_1} = \text{expit}(\alpha_1 + \phi_{L_1}L_1 + \phi_{M_1}M_1 + \phi_{N_1}N_1 + \phi_{O_1}O_1 + \phi_{P_1}P_1 + \phi_{Q_1}Q_1 + \phi_{T_1}T_1 + \phi_{R_1}R_1 + \phi_{V_1}V_1 + \phi_{Z_1}Z_1 + \theta A_0))$
7. Outcome: $Y \sim \text{Bern}(p_Y = \text{expit}(\alpha_Y + \sum_{j=0}^1 \beta_{L_j}L_j + \sum_{j=0}^1 \beta_{M_j}M_j + \sum_{j=0}^1 \beta_{N_j}N_j + \sum_{j=0}^1 \beta_{O_j}O_j + \sum_{j=0}^1 \beta_{P_j}P_j + \sum_{j=0}^1 \beta_{Q_j}Q_j + \sum_{j=0}^1 \beta_{T_j}T_j + \sum_{j=0}^1 \beta_{R_j}R_j + \sum_{j=0}^1 \beta_{V_j}V_j + \sum_{j=0}^1 \beta_{Z_j}Z_j + \beta_{A_0}A_0 + \beta_{A_1}A_1))$

3.3 | Description of the simulation scenarios

In this section we provide a description of the ten different scenarios we have run. We first describe the base case scenario and then describe how each scenario differs from this base case scenario. Scenarios 1, 2, 3, 7, 8, 9 and 10 were based on *Franklin et al*⁷ and the detailed for covariate parameters for simulations studies can be found in Appendix 1 in the Supporting information.

Scenario 1 (Base case): In this scenario, we used a sample size of $n = 10,000$ and did not include the covariates T_t , R_t , V_t and Z_t , $t = 0, 1$ in the treatment or outcome generating equations (i.e., we set $\phi_{T_t} = \beta_{T_t} = 0$, $\phi_{R_t} = \beta_{R_t} = 0$, $\phi_{V_t} = \beta_{V_t} = 0$, $\phi_{Z_t} = \beta_{Z_t} = 0$). Recall that these covariates represent non-linear terms. We then chose values for α_0 and α_1 such that approximately 50% of individuals were treated at each time-point. In addition, we chose values for α_Y so that the overall outcome prevalence was approximately 20%. For each time-point, we simulated the variables O_t and P_t with prevalences of 50% and 20%, respectively. Finally, we specified that $\beta = 0$ indicating no effect of the covariates X_0 on the covariates X_1 . This choice reduces the collinearity between the imbalance variables that measure the imbalance at different time-points and thus facilitates the interpretation of the simulation results.

Scenario 2 (Low prevalence of exposure): We chose $\alpha_0 = -3.08$, $\alpha_1 = -3.37$ and $\alpha_Y = -5.1$ such that 20% of individuals were treated at each time-point and overall outcome prevalence was approximately 20%.

Scenario 3 (Small sample): We used a smaller sample size of $n = 1,000$.

Scenarios 4, 5 and 6 were designed to evaluate the performance of the metrics when the data is highly imbalanced or weakly imbalanced.

Scenario 4 (High imbalance, no confounding): All covariates are strongly associated with treatment at each time-point (larger values for the ϕ parameters) and had no effect on the outcome ($\beta_{X_0} = \beta_{X_1} = 0$).

Scenario 5 (Low imbalance, moderate confounding): All covariates at both time-points are weakly associated with treatment, the treatment at both time-points had no effect on the outcome ($\beta_{A_0} = \beta_{A_1} = 0$) and covariates had strong relations with the outcome (large β_{X_0} and β_{X_1} values).

It should be noted that the degree of bias depends on the magnitude of the effect of the covariate on the outcome in addition to the amount of imbalance. More precisely, for a given level of imbalance, a weaker bias is expected when the covariates are weakly prognostic of the outcome than when the covariates are strongly prognostic of the outcome. Because the balance metrics we considered do not incorporate information about the associations of covariates with the outcome, we expected that all metrics would perform poorly in Scenarios 4 and 5.

Scenario 6 (High imbalance-high confounding): We chose larger values for the ϕ and β parameters to create datasets with high imbalance and relatively high confounding at each time-point.

Scenarios 7 and 8 were designed to evaluate the performance of balance metrics when the outcome or treatment are a non-linear function of the covariates (e.g., body mass index).

Scenario 7 (Nonlinear outcome): We included the covariates T , R , V and Z in the outcome generating equation (i.e. $\phi_{T_t} = \phi_{R_t} = \phi_{V_t} = \phi_{Z_t} = 0, \beta_{T_t} \neq 0, \beta_{R_t} \neq 0, \beta_{V_t} \neq 0, \beta_{Z_t} \neq 0$), $t = 0, 1$

Scenario 8 (Nonlinear outcome and exposure): We included the covariates T , R , V and Z in the outcome and treatment generating equations (i.e. all ϕ and β parameters are not equal to zero).

Scenario 9 (Redundant Covariates): This scenario was designed to understand the advantages of the MHB, which uses covariance between variables to avoid over-penalizing the imbalance on several highly correlated covariates. We included the covariates T , R , V and Z in the outcome and treatment generating equations and specified that O_0 and O_1 had no effect on the treatments or outcome by setting the coefficients to zero on all terms of the treatments or outcome generating model involving O_0 and O_1 (ie, $\phi_{O_0} = \phi_{O_1} = 0, \beta_{O_0} = \beta_{O_1} = 0$). As such, because L_0 and O_0 , as well as L_1 and O_1 , are highly correlated but only L_0 and L_1 affect the exposure and the outcome, O_0 and O_1 are redundant variables.

Scenario 10 (Instrumental variables): This scenario was designed to assess the performance of the balance metrics when there are instrumental variables present in the set of covariates to be balanced. Indeed, adjustment for the latter is known to increase the variance of the estimators and is likely to amplify the bias in the treatment effect estimate^{26,27}. We included the covariates T , R , V and Z in the outcome and treatment generating equations and specified that the covariates M_0 and M_1 were instrumental variables by setting to zero the coefficients related to these variables in the outcome generating equation (i.e. $\beta_{M_0} = \beta_{M_1} = \beta_{R_0} = \beta_{R_1} = 0$).

3.4 | Results

Figure 2 shows the distributions of the propensity score at each time-point for an example of one dataset of the base case scenario without censoring. The unweighted data were highly imbalanced. With both propensity score specifications (simple or complex), the balance on the propensity score improved in data weighted by $W_0 \times W_1$, and the two groups had very similar distributions at each time-point. In contrast, the data weighted by W_1 only were highly imbalanced at time $t = 0$ and well balanced at time $t = 1$. The opposite result is obtained when the data are weighted by W_0 only. Similarly in the data weighted by the product of W_0 truncated at the 90th percentile with W_1 , the data are moderately imbalanced at time $t = 0$ and well balanced at time $t = 1$. Finally, in the data weighted by the product of W_0 and W_1 truncated at the 90th percentile, the data are well balanced at time $t = 0$ and moderately imbalanced at time $t = 1$. The results for the base case with censoring are similar and are presented in Appendix 4 in the Supporting information. Likewise results for all other simulation scenarios are presented in Appendix 4 in the Supporting information.

Table 1 presents the average bias and the average imbalance for each of the eight balance metrics for the base case scenario with uncensored and censored data. We present the results just for the simple propensity score because the two specifications for the propensity score provided nearly identical results. The objective is to determine whether the calculated balance metrics are consistent with the true balances as in the Figure 2 and whether the calculated balances are consistent with the bias. An ideal balance metric would show high imbalance between groups A_0 by covariates X_0 or high imbalance between groups A_1 by covariates X_1 when the estimates are biased, and low (near zero) imbalance when the bias approaches zero. Apart from OVL and CS, all other calculated balance metrics are consistent with true imbalance. In addition, the effect estimates are biased in the




FIGURE 2 Distributions of the propensity score in an example dataset of the base case simulation scenario without censoring with different types of weights. The red curve corresponds to the treated group and the blue curve to the untreated. Odd panels correspond to the distribution at $t = 0$ and even panels to the distribution at $t = 1$. The first row (panels 1-2) correspond to unweighted data, the second (panels 3-4) to data weighted by $W_0 \times W_1$, the third (panels 5-6) to data weighted by W_1 only, the fourth (panels 7-8) to data weighted according to W_0 only, the fifth (panels 9-10) to the product of W_0 truncated at the 90th percentile with W_1 and the last row (panels 11-12) to the product of W_0 with W_1 truncated at the 90th percentile.

unweighted data and in the data weighted by W_0 or W_1 only. These biases decreased in the data weighted by the other three weights. Tables for the other simulation scenarios are presented in Appendix 2 of the Supporting information.

Table 2 and 3 summarizes the estimated intercept and explained variation (R^2) for each of the eight metrics in all scenarios for the uncensored and censored data setting. Almost all imbalance metrics were strongly associated with bias. In particular for the base case (Scenario 1), the performance of D, SMD, KS, LD, MHB and GWD in terms of R^2 is similar, with R^2 ranging from 93% to 94%. However, the intercept for MHB was closer to 0 than that of the other metrics, indicating a better fit between MHB and bias. In contrast, OVL and CS had a consistently weaker association with bias than most other measures of balance and OVL had intercept far from 0, indicative that substantial bias could be present even when this metric did not detect any imbalance. The results for the other scenarios are overall in line with those of the base case scenario. Of note, in the low imbalance moderate confounding (Scenario 5) and the low sample size (Scenario 3) scenarios, all metrics were moderately less good at predicting bias, but the comparative performance of the metrics remained unchanged. In addition, all metrics were poor at predicting bias in the high imbalance no confounding (Scenario 4) scenario and in the censored data setting.

TABLE 1 Average covariate imbalances across covariates at each time-point and average bias for the base case scenario. Averages are taken over 1,000 simulated datasets in the unweighted data and in data weighted according to the five weights.

Uncensored data													
	D			SMD			OVL			KS			Bias
Unweighted	1.44	0.08	1.42	0.32	0.02	0.29	0.42	0.33	0.41	0.14	0.02	0.12	0.29
$W_0 \times W_1$	0.05	0.05	0.05	0.02	0.02	0.02	0.36	0.34	0.36	0.02	0.02	0.02	0.01
W_1	1.44	0.02	0.03	0.32	0.01	0.01	0.42	0.33	0.35	0.14	0.01	0.01	0.11
W_0	0.03	0.05	1.42	0.01	0.02	0.29	0.36	0.34	0.41	0.01	0.02	0.12	0.09
$W_0 \text{tr}90 \times W_1$	0.51	0.02	0.03	0.11	0.01	0.01	0.38	0.34	0.35	0.05	0.01	0.01	0.02
$W_0 \times W_1 \text{tr}90$	0.03	0.04	0.50	0.01	0.01	0.10	0.36	0.34	0.37	0.01	0.01	0.05	0.02
	LD			MHB			CS			GWD			Bias
Unweighted	0.12	0.01	0.11	1.09	0.00	1.01	0.54	0.53	0.53	0.17	0.01	0.15	0.29
$W_0 \times W_1$	0.01	0.01	0.01	0.00	0.00	0.00	0.05	0.04	0.04	0.01	0.01	0.01	0.01
W_1	0.12	0.01	0.01	1.09	0.00	0.00	0.54	0.05	0.05	0.17	0.01	0.01	0.11
W_0	0.01	0.01	0.11	0.00	0.00	1.01	0.05	0.52	0.52	0.01	0.01	0.15	0.09
$W_0 \text{tr}90 \times W_1$	0.04	0.01	0.01	0.13	0.00	0.00	0.54	0.04	0.04	0.06	0.01	0.01	0.02
$W_0 \times W_1 \text{tr}90$	0.01	0.01	0.04	0.00	0.00	0.13	0.04	0.52	0.52	0.01	0.01	0.06	0.02
Censored data													
	D			SMD			OVL			KS			Bias
Unweighted	1.38	0.08	1.42	0.29	0.02	0.29	0.42	0.33	0.41	0.12	0.02	0.12	0.28
$W_0^{A,C} \times W_1^{A,C}$	0.06	0.05	0.05	0.02	0.02	0.02	0.37	0.34	0.36	0.02	0.02	0.02	0.01
$W_1^{A,C}$	1.44	0.02	0.03	0.32	0.01	0.01	0.43	0.34	0.35	0.14	0.01	0.01	0.12
$W_0^{A,C}$	0.04	0.06	1.42	0.01	0.02	0.29	0.37	0.34	0.41	0.01	0.02	0.12	0.10
$W_0^{A,C} \text{tr}90 \times W_1^{A,C}$	0.51	0.02	0.04	0.11	0.01	0.01	0.38	0.34	0.35	0.05	0.01	0.01	0.03
$W_0^{A,C} \times W_1^{A,C} \text{tr}90$	0.04	0.05	0.50	0.02	0.02	0.10	0.37	0.34	0.37	0.02	0.02	0.05	0.03
	LD			MHB			CS			GWD			Bias
Unweighted	0.11	0.01	0.11	1.00	0.00	1.01	0.52	0.53	0.53	0.15	0.01	0.15	0.28
$W_0^{A,C} \times W_1^{A,C}$	0.01	0.01	0.01	0.00	0.00	0.00	0.03	0.03	0.03	0.01	0.01	0.01	0.01
$W_1^{A,C}$	0.13	0.01	0.01	1.09	0.00	0.00	0.52	0.04	0.04	0.17	0.01	0.01	0.12
$W_0^{A,C}$	0.01	0.01	0.11	0.00	0.01	1.01	0.02	0.52	0.52	0.01	0.01	0.15	0.10
$W_0^{A,C} \text{tr}90 \times W_1^{A,C}$	0.04	0.01	0.01	0.13	0.00	0.00	0.52	0.03	0.03	0.06	0.01	0.01	0.03
$W_0^{A,C} \times W_1^{A,C} \text{tr}90$	0.01	0.01	0.04	0.00	0.00	0.13	0.02	0.52	0.52	0.01	0.01	0.06	0.03

For each imbalance metric, the three columns represent the mean imbalance between groups A_0 by covariates X_0 , mean imbalance between groups A_1 by covariates X_0 and mean imbalance between groups A_1 by covariates X_1 , respectively. $W_0 \text{tr}90$ is W_0 truncated at the 90th percentile and $W_1 \text{tr}90$ is W_1 truncated at the 90th percentile.

4 | ILLUSTRATION

We now illustrate the use of our methods in real data concerning the effectiveness of statins for the prevention of a first cardiovascular event among older adults, that is, for primary prevention. Several randomized studies indicate that statins have major benefits for primary prevention in certain populations^{28,29,30,31}. However, few studies inform about the real-world benefits in people aged 65 years and older for primary prevention³². Population-wide administrative data could provide crucial evidence because their large sample size and population representativeness allow studying populations that are typically excluded or under-represented in randomized studies. We thus conducted a retrospective cohort study using medico-administrative data from Quebec, Canada. This project was approved by the research ethics board of the research center of the CHU of Quebec (decision #2020 – 4892). The purpose of the illustrative study was to estimate the hazard reduction of a first cardiovascular event or death associated to patients' treatment compliance within the first year of treatment.

4.1 | Data

We formed a retrospective cohort using data available at the *Institut de la statistique du Québec* by merging data from five medical administrative databases in Québec, Canada using a unique anonymized personal identifier: the health insurance registry,

TABLE 2 Estimated intercept (β_0) for each balance metrics in ten simulation scenarios and the explained variation (R^2) for each balance metric.

Simple propensity score										
	Scenario 1		Scenario 2		Scenario 3		Scenario 4		Scenario 5	
	R^2	β_0	R^2	β_0	R^2	β_0	R^2	β_0	R^2	β_0
D	0.94	-0.05	0.89	-0.04	0.66	-0.05	0.08	0.01	0.60	0.00
SMD	0.94	-0.07	0.90	-0.06	0.67	-0.07	0.09	0.03	0.61	0.00
OVL	0.91	-11.24	0.89	-0.84	0.57	-1.62	0.11	1.10	0.54	80.01
KS	0.94	-0.14	0.89	-0.11	0.65	-0.15	0.11	0.02	0.59	-0.09
LD	0.94	-0.10	0.89	-0.09	0.66	-0.12	0.11	0.02	0.59	-0.03
MHB	0.93	-0.03	0.89	-0.03	0.66	-0.02	0.11	0.01	0.59	0.01
CS	0.58	-0.09	0.58	-0.10	0.46	-0.09	0.01	0.02	0.38	-0.04
GWD	0.94	-0.08	0.90	-0.07	0.67	-0.10	0.10	0.02	0.61	-0.02
	Scenario 6		Scenario 7		Scenario 8		Scenario 9		Scenario 10	
	R^2	β_0	R^2	β_0	R^2	β_0	R^2	β_0	R^2	β_0
D	0.87	-0.55	0.94	-0.07	0.93	-0.06	0.87	-0.02	0.93	-0.03
SMD	0.89	-0.52	0.94	-0.09	0.94	-0.08	0.88	-0.02	0.93	-0.02
OVL	0.84	-13.98	0.90	-0.57	0.89	-0.33	0.81	3.63	0.89	5.03
KS	0.88	-0.79	0.94	-0.20	0.94	-0.18	0.87	-0.05	0.93	-0.03
LD	0.87	-0.69	0.94	-0.13	0.94	-0.11	0.88	-0.03	0.93	-0.02
MHB	0.90	-0.32	0.93	-0.04	0.93	-0.04	0.87	-0.01	0.93	-0.01
CS	0.57	-0.65	0.58	-0.11	0.59	-0.09	0.57	-0.04	0.63	-0.06
GWD	0.89	-0.57	0.94	-0.11	0.94	-0.10	0.88	-0.03	0.93	-0.03

Complex propensity score										
	Scenario 1		Scenario 2		Scenario 3		Scenario 4		Scenario 5	
	R^2	β_0	R^2	β_0	R^2	β_0	R^2	β_0	R^2	β_0
D	0.94	-0.05	0.89	-0.04	0.66	-0.05	0.08	0.00	0.60	0.00
SMD	0.94	-0.06	0.89	-0.06	0.66	-0.07	0.09	0.02	0.61	0.00
OVL	0.91	-9.55	0.88	-1.57	0.56	-1.88	0.10	1.08	0.54	68.73
KS	0.94	-0.13	0.89	-0.11	0.65	-0.13	0.10	0.01	0.59	-0.11
LD	0.94	-0.09	0.89	-0.09	0.66	-0.11	0.10	0.01	0.59	-0.03
MHB	0.93	-0.03	0.89	-0.03	0.66	-0.02	0.10	0.01	0.59	0.01
CS	0.65	-0.08	0.66	-0.09	0.52	-0.08	0.01	0.01	0.41	-0.04
GWD	0.94	-0.07	0.90	-0.07	0.66	-0.09	0.10	0.02	0.61	-0.01
	Scenario 6		Scenario 7		Scenario 8		Scenario 9		Scenario 10	
	R^2	β_0	R^2	β_0	R^2	β_0	R^2	β_0	R^2	β_0
D	0.87	-0.55	0.94	-0.06	0.93	-0.06	0.88	-0.03	0.93	-0.03
SMD	0.90	-0.53	0.94	-0.08	0.94	-0.07	0.88	-0.03	0.94	-0.03
OVL	0.84	-14.59	0.90	-0.96	0.89	-1.56	0.81	2.53	0.90	5.03
KS	0.88	-0.80	0.94	-0.18	0.94	-0.16	0.88	-0.06	0.94	-0.06
LD	0.87	-0.70	0.94	-0.12	0.94	-0.11	0.88	-0.03	0.94	-0.03
MHB	0.91	-0.32	0.93	-0.04	0.93	-0.04	0.87	-0.02	0.93	-0.01
CS	0.66	-0.63	0.65	-0.11	0.05	0.05	0.65	-0.04	0.70	-0.06
GWD	0.89	-0.58	0.94	-0.10	0.93	-0.09	0.88	-0.04	0.94	-0.04

Scenario 1 is the base case, Scenario 2 is the low prevalence of exposure case, Scenario 3 is the small sample case, Scenario 4 is the high imbalance, no confounding case, Scenario 5 is the low imbalance sample case, Scenario 6 is the high imbalance-high confounding case, Scenario 7 is the nonlinear outcome case, Scenario 8 is the nonlinear outcome and exposure case, Scenario 9 is the redundant covariates case, Scenario 10 is the instrumental variables case.

the pharmaceutical services database, the physician claims database, the hospitalization database and the death registry. The cohort included Quebecers aged 66 or older as of April 1, 2013, who were beneficiaries of Quebec's public drug insurance plan without interruption for the previous year. Individuals with a statin dispensation in the previous year (between April 1, 2012, and March 31, 2013) and those with a history of cardiovascular disease (myocardial infarction, heart failure and other ischemic heart disease, cerebrovascular disease, and atherosclerosis) in the past 5 years (April 1, 2008, to March 31, 2013) were excluded to ensure that only primary prevention statin users were included. To control the risk of confounding by indication, only individuals who received at least one statin dispensation between April 2012 and March 2017 were included in this analysis resulting in a sample of 32,690 statin initiators. Each individual's exposure status was updated monthly up to 12 months after their first statin dispensation up to 12 months later. An individual was considered as exposed in a given month if they had a filled

TABLE 3 Estimated intercept (β_0) for each balance metrics in the base case scenario with censoring and the explained variation (R^2) for each balance metric.

	R^2	β_0
D	0.92	-0.03
SMD	0.92	-0.06
OVL	0.88	10.90
KS	0.92	-0.13
LD	0.92	-0.09
MHB	0.92	-0.02
CS	0.59	-0.07
GWD	0.92	-0.08

statin prescription covering at least one day of that month, after accounting for a 50% grace period. Follow-up for the outcome began immediately after the 12-month exposure follow-up and until the earliest of the following: occurrence of a cardiovascular event, death, termination of public drug plan membership, admission to a long-term care facility, or March 31, 2018, for a total of 386,422 person-months of follow-up. To adjust for selection bias when estimating the effect of statins, we used inverse probability censoring weights. We considered that all individuals having one of the following events: cardiovascular disease during exposure follow-up, death during exposure follow-up or termination of public drug plan membership during exposure follow-up were censored.

Using the notation introduced in this paper, the data set contained the following information about each subject:

1. $C_t = 1$, if an individual is censored at the beginning of month t , ($C_t = 0$ otherwise).
2. X_0, \dots, X_{11} the set of covariates (potential confounders) measured at months 0, ..., 11. These include both time-fixed covariates measured at baseline only (sex, age and region of residence) and time-varying covariates whose values were updated monthly (prevalent diabetes, hypertension, chronic renal failure, use of aspirin and other antiplatelet agents and pharmacological treatment of blood pressure). These factors were identified as potential confounders on the basis of a literature review and experts' opinions.
3. Statin exposure ($A_t = 1$) or non-exposure ($A_t = 0$) in month t , $t = 0, \dots, 11$.
4. A binary outcome (Y) measured after exposure follow-up ($Y = 1$ if the individual experiences a cardiovascular event or all-cause death during the outcome follow-up and 0 otherwise).

4.2 | Analysis

Because of the time-to-event nature of the outcome, our goal was to estimate the parameters of the marginal structural Cox model $\lambda_{\bar{a}_t}(\tau) = \lambda_0(\tau) \exp(\beta \sum_{t=0}^{11} a_t + \beta_1 V)$, where V is set of baseline or time-invariant confounders using an inverse probability weighting estimator^{2,33}. We first estimated the probability of statin exposure at each time-point (month $t = 0$ to month $t = 11$) as a function of pretreatment characteristics (baseline and time-varying covariates) using logistic regressions. The treatment weights were then estimated as the inverse of the probabilities of the observed exposure status at each time-point. Censoring weights were calculated analogously. Marginal stabilized weights were used to check for covariate balance, and stabilized weights were used to estimate the effect of statin history. For each individual, we multiplied their treatment weight and censoring weight from month 0 to month 11 to obtain a total weight. Because of the presence of extreme weights, we truncated the total weights at the 99th percentile as suggested in previous studies^{33,34}.

Based on our simulation results, we decided to first check balance between treatment groups at each time-point using a global metric, the MHB. As we proposed in previous sections, we consider all the covariates measured at a given time-point jointly, but covariates measured at different time-points separately. If a global imbalance was found at a particular time-point, we would then use SMDs to more finely assess which covariates were imbalanced. Using this procedure, we assessed the balance both in the unweighted data and in the weighted data. As we did previously³⁴, we only assessed covariate balance between treatment groups after period 3, because very few participants were non-users in first three periods (0%, 0.3% and 6.3% respectively).

4.3 | Results

Table 4 describes the baseline characteristics of the population. As required by *Institut de la statistique du Québec* confidentiality rules, note that all frequencies were rounded in base five. The mean age of the participants was 71.96 years, 57.1% were women, 16% had a diabetes diagnosis and 61.2% received blood pressure treatment.

Table 5 reports the balance results. Given that 19 variables were examined (after considering dummy variables as separate variables) for time-fixed covariates and that 7 variables were examined for time-varying covariates the threshold for assessing that distribution of the covariates differed meaningfully between treatment group was 0.19 and 0.07 respectively. All time-fixed covariates were well balanced in both unweighted and weighted data. For time-varying covariates exposure groups were relatively imbalanced before weighting at each time-point, with the largest MHB being 0.17. Weighting improved overall covariate balance at all time-points except balance of covariates at time $t = 1, 2, 3, 7$ between the A_7 treatment groups. To detect problematic covariates, we used the SMD. We found that the number of medications in the year of statin initiation, number of days of hospitalization in the year of statin initiation and Use of aspirin and other antiplatelet agents were imbalanced. We recalculated the weights by including in the treatment model quadratic terms for the number of medications in the year of statin initiation and number of days of hospitalization in the year of statin initiation, and an interaction term between Use of aspirin and other antiplatelet agents and number of medications in the year of statin initiation on one hand and between Use of aspirin and other antiplatelet agents and number of days of hospitalization in the year of statin initiation on the other hand. The overall balance improved at times $t = 1, 2$, from 0.08 to 0.07, but remained unchanged at times $t = 3, 7$. Despite several attempts to modify the treatment model, these imbalances remained.

Before adjustment, each additional month of statin exposure during the first year of treatment was associated, within the following 5 years, with 3% reduction of the hazard of a first cardiovascular event or death (HR = 0.97, 95% CI: 0.96 – 0.98). Very similar results were obtained after adjustment for potential confounding and censoring bias (HR = 0.97, 95% CI: 0.96 – 0.98). It should be noted that the treatment compliance within the first year is most likely correlated with compliance in the following years. Because we were unable to fully balance treatment groups, some relatively low residual confounding due to measured confounders is expected.

TABLE 4 Participant characteristics at baseline

Characteristic	N = 32,690
Age (mean (SD))	71.96 (5.69)
Women n (%)	18,670 (57.1)
Socio-sanitary area n (%)	
Bas Saint Laurent	1,080 (3.3)
Saguenay-Lac Saint Jean	1,060 (3.2)
Capitale Nationale	2,345 (7.2)
Mauricie et Centre du Québec	2,440 (7.5)
Estrie	2,090 (6.4)
Montréal	7,585 (23.2)
Outaouais	1,040 (3.2)
Abitibi-Témiscamingue	580 (1.8)
Côte-Nord	355 (1.1)
Gaspésie-les de la Madeleine	555 (1.7)
Chaudière Appalaches	2,065 (6.3)
Laval	1,655 (5.1)
Lanaudière	2,185 (6.7)
Laurentides	2,370 (7.2)
Montérégie	5,130 (15.7)
Terres Cries de la Baie James and Nord du Québec	55 (0.2)
Prevalent diabetes, (yes, n(%))	5,240 (16)
Hypertension, (yes, n(%))	8,120 (24.8)
Number of filled prescriptions in the year of statin initiation, (mean (SD))	4.21 (3.80)
Number of days of hospitalization in the year of statin initiation, (mean (SD))	0.21 (0.59)
Use of aspirin and other antiplatelet agents (yes, n(%))	1,005 (3.1)
Chronic kidney disease, (yes, n(%))	135 (0.4)
Blood pressure treatment, (yes, n(%))	19,995 (61.2)

5 | DISCUSSION

In this article, we have first extended the definition of several balance metrics from the point-exposure setting to the case of a time-varying treatment in the presence of censoring, including a new variant of the Mahalanobis balance. We have compared the performance of these balance metrics at signaling potential bias in a simulation study with two time-points. We found that, apart from the overlap coefficient and the post-weighted C-statistic, all other imbalance metrics were strongly associated with bias, but the Mahalanobis balance offered the best performance. In the light of these results, we recommend using the Mahalanobis balance first as a global measure of imbalance, and then using individual-level metrics such the standardised mean difference to determine which variables are imbalanced if required. To support the practical implementation of this recommendation, we provide R code on GitHub (<https://github.com/deta19/LongitudinalBalanceMetrics>). We have also illustrated the implementation of our recommended approach in estimating the effect of cumulative statin exposure on cardiovascular disease risk in the older population using an inverse probability weighted marginal structural model. In this application, weighting substantially improved the overall balance of covariates as measured with Mahalanobis balance. After adjustment for confounding and censoring, each additional month of statin exposure was associated with a 3% reduction of the hazard of a first cardiovascular event or death.

To the best of our knowledge, only Jackson *et al*³ and Greifer N¹¹ had previously studied balance metrics with a time-varying treatment. Unlike them, we propose checking the balance between treatment groups using marginal stabilized weights instead of the usual stabilized weights. This choice significantly reduces the burden of checking balance between groups. As mentioned in Section 3, stabilized weights only balance treatment groups conditional on past treatment. As such, one must check balance between treatment groups conditional on each possible treatment history when considering stabilized weights. Marginal

TABLE 5 Covariates balance at each time-point between statin users and non-users in unweighted data and in data weighted by IPTW \times IPCW

		$A_3 = 1$ vs $A_3 = 0$		$A_4 = 1$ vs $A_4 = 0$		$A_5 = 1$ vs $A_5 = 0$	
		Unweighted	Weighted	Unweighted	Weighted	Unweighted	Weighted
Time-fixed covariates		0.06	0.07	0.06	0.10	0.05	0.11
Time-varying covariates							
	0	0.04	0.07	0.04	0.04	0.04	0.01
	1	0.07	0.06	0.06	0.03	0.06	0.02
	2	0.12	0.05	0.09	0.03	0.08	0.02
Time-point	3	0.17	0.03	0.13	0.02	0.11	0.02
	4			0.15	0.02	0.13	0.02
	5					0.15	0.02
		$A_6 = 1$ vs $A_6 = 0$		$A_7 = 1$ vs $A_7 = 0$		$A_8 = 1$ vs $A_8 = 0$	
		Unweighted	Weighted	Unweighted	Weighted	Unweighted	Weighted
Time-fixed covariates		0.05	0.05	0.05	0.03	0.05	0.05
Time-varying covariates							
	0	0.04	0.01	0.04	0.06	0.04	0.01
	1	0.06	0.01	0.06	0.07	0.05	0.02
	2	0.08	0.01	0.08	0.07	0.07	0.02
	3	0.10	0.01	0.10	0.08	0.09	0.01
Time-point	4	0.11	0.02	0.11	0.07	0.10	0.01
	5	0.13	0.02	0.12	0.07	0.12	0.02
	6	0.15	0.03	0.14	0.05	0.13	0.02
	7			0.15	0.08	0.14	0.01
	8					0.15	0.01
		$A_9 = 1$ vs $A_9 = 0$		$A_{10} = 1$ vs $A_{10} = 0$		$A_{11} = 1$ vs $A_{11} = 0$	
		Unweighted	Weighted	Unweighted	Weighted	Unweighted	Weighted
Time-fixed covariates		0.05	0.05	0.05	0.03	0.05	0.05
Time-varying covariates							
	0	0.04	0.04	0.04	0.02	0.04	0.02
	1	0.05	0.04	0.05	0.02	0.05	0.02
	2	0.07	0.04	0.07	0.02	0.07	0.02
	3	0.09	0.04	0.09	0.02	0.08	0.02
	4	0.10	0.04	0.10	0.03	0.09	0.02
Time-point	5	0.11	0.05	0.11	0.03	0.10	0.02
	6	0.12	0.05	0.11	0.03	0.11	0.02
	7	0.13	0.04	0.12	0.02	0.11	0.02
	8	0.14	0.04	0.13	0.02	0.12	0.02
	9	0.15	0.03	0.14	0.02	0.13	0.03
	10			0.16	0.02	0.14	0.04
	11					0.16	0.02

stabilized weights do not share this limitation and allows checking balance between groups unconditionally of previous treatment history. Our simulation study supports the validity of our proposed approach. Our application to population-wide administrative data with 12 time-points further supports the applicability of our methods in practice in large databases with multiple time-points. In this application with 12 time-points, we have to check 77 balances using marginal stabilized weight, compared with 22,528 if we had used stabilized weights. This choice has thus considerably reduced the computation burden and improved feasibility.

Despite the strengths of the proposed method, certain limitations must be taken into account. A first important limitation is that it is not known what limit of Mahalanobis balance would be acceptable from the point of view of bias. Our proposed threshold is

based on connections with the standardized mean difference, for which the a commonly accepted threshold is 0.1^{5,7}, under the assumptions that covariates are uncorrelated. Extensive simulations would be required to assess the validity of this threshold under various scenarios, or to propose an alternative threshold. However, as illustrated in our simulations, a second limitation is that there are scenarios where bias is poorly associated with imbalance. For example, if the imbalance concerns a variable with little association with the response, then even a high level of imbalance can generate a low or moderate bias (scenario 4). However, in the case of a variable highly associated with the response, even a small imbalance can generate a considerable bias (scenario 5). This second limitation highlights the challenge of establishing an acceptable threshold of imbalance for any balance metric. A potential solution would be to use metrics that take into account the covariate-outcome relationship. Such metrics have been proposed for the cross-sectional case⁶, but have not yet been extended to the longitudinal case. However, this approach would contradict the principle accepted by many of separating the study design stage (i.e., balancing the treatment groups) from the response analysis step³⁵.

Our current work could be extended in several directions. For example, apart from the general weighted difference, the balance metrics described in this article, in particular the Mahalanobis balance, do not take into account the overall imbalance on all covariate squares and pairwise interactions. As suggested by⁵, higher-order moments and interactions between variables should be similar between treatment groups in the weighted sample. Future work would be to extend the Mahalanobis balance to account for global imbalance on all covariate squares and all pairwise interactions using a matrix version of the general weighted difference metric. In conclusion, we believe that better checking of covariates balance following our recommendations will improve the current practice of using IPTW to estimate time-varying treatment effects.

FUNDING INFORMATION

This work was supported by a grant from the Canadian Institutes of Health Research (# 420060). JRG, CS and DT are supported by research career awards from the *Fonds de recherche du Québec – Santé*.

DATA AVAILABILITY STATEMENT

All R codes used in the simulation study are available on <https://github.com/deta19/LongitudinalBalanceMetrics>. The data from the *Institut de la statistique du Québec* are not publicly available. Access to these data is managed by the Data Access Service of *Institut de la statistique du Québec* under Québec provincial laws.

ORCID

References

1. Robins JM, Hernán MA, Brumback BA. Marginal structural models and causal inference in epidemiology. *Epidemiology*. 2000;11(5):550–560.
2. Hernán MÁ, Brumback B, Robins JM. Marginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive Men. *Epidemiology*. 2000;11(5):561–570.
3. Jackson JW. Diagnostics for confounding of time-varying and other joint exposures. *Epidemiology*. 2016. doi: 10.1097/EDE.0000000000000547
4. VanderWeele TJ, Jackson JW, Li S. Causal inference and longitudinal data: a case study of religion and mental health. *Social psychiatry and psychiatric epidemiology*. 2016;51:1457–1466.
5. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Statistics in Medicine*. 2015;34(28):3661–79.
6. Belitser SV, Martens EP, Pestman WR, Groenwold RHH, Boer dA, Klungel OH. Measuring balance and model selection in propensity score methods. *Pharmacoepidemiology and Drug Safety*. 2011;20(11):1115–1129. doi: <https://doi.org/10.1002/pds.2188>
7. Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S. Metrics for covariate balance in cohort studies of causal effects. *Statistics in Medicine*. 2014;33(10):1685–1699. doi: 10.1002/sim.6058
8. Rubin DB. Bias Reduction Using Mahalanobis-Metric Matching. *International Biometric Society*. 1980;36(2):293–298.
9. Austin P. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Statistics in Medicine*. 2009;28:3083–3107. doi: 10.1002/sim.3697
10. Stefano M, Iacus GK, Porro G. Multivariate Matching Methods That Are Monotonic Imbalance Bounding. *Journal of the American Statistical Association*. 2011;106(493):345–361. doi: 10.1198/jasa.2011.tm09599
11. Greifer N. cobalt: Covariate Balance Tables and Plots. *R Package Version 4.5.3*. 2024.

12. Thoemmes F, Ong AD. A primer on inverse probability of treatment weighting and marginal structural models. *Emerging Adulthood*. 2016;4(1):40–59.
13. Cole SR, Hernán MA. Constructing Inverse Probability Weights for Marginal Structural Models. *American Journal of Epidemiology*. 2008;168(6):656–664. doi: [10.1093/aje/kwn164](https://doi.org/10.1093/aje/kwn164)
14. Sall A, Aubé K, Trudel X, Brisson C, Talbot D. A test for the correct specification of marginal structural models. *Statistics in Medicine*. 2019;38(17):3168–3183. doi: <https://doi.org/10.1002/sim.8132>
15. Agresti A. *Categorical data analysis*. 792. John Wiley & Sons, 2012.
16. Markoulidakis A, Taiyari K, Holmans P, et al. A tutorial comparing different covariate balancing methods with an application evaluating the causal effects of substance use treatment programs for adolescents. *Health Services and Outcomes Research Methodology*. 2023;23(2):115–148. doi: [10.1007/s10742-022-00280-0](https://doi.org/10.1007/s10742-022-00280-0)
17. Lee BK, Lessler J, Stuart EA. Weight Trimming and Propensity Score Weighting. *PLoS ONE*. 2011;6(4). doi: [10.1371/journal.pone.0018174](https://doi.org/10.1371/journal.pone.0018174)
18. Setoguchi S, Schneeweiss S, Brookhart MA, Glynn RJ, Cook EF. Evaluating uses of data mining techniques in propensity score estimation: a simulation study. *Pharmacoepidemiology and drug safety*. 2008;17(6):546–555.
19. Westreich D, Lessler J, Funk MJ. Propensity score estimation: neural networks, support vector machines, decision trees (CART), and meta-classifiers as alternatives to logistic regression. *Journal of Clinical Epidemiology*. 2010;63(8):826–833. doi: <https://doi.org/10.1016/j.jclinepi.2009.11.020>
20. Pirracchio R, Petersen ML, Laan v. dM. Improving Propensity Score Estimators' Robustness to Model Misspecification Using Super Learner. *American Journal of Epidemiology*. 2014;181(2):108–119. doi: [10.1093/aje/kwu253](https://doi.org/10.1093/aje/kwu253)
21. Diop SA, Duchesne T, G. Cumming S, Diop A, Talbot D. Confounding adjustment methods for multi-level treatment comparisons under lack of positivity and unknown model specification. *Journal of Applied Statistics*. 2022;49(10):2570–2592. doi: [10.1080/02664763.2021.1911966](https://doi.org/10.1080/02664763.2021.1911966)
22. Naimi AI, Mishler AE, Kennedy EH. Challenges in Obtaining Valid Causal Effect Estimates With Machine Learning Algorithms. *American Journal of Epidemiology*. 2021;192(9):1536–1544. doi: [10.1093/aje/kwab201](https://doi.org/10.1093/aje/kwab201)
23. Moodie EEM, Delaney JA, Lefebvre G, Platt RW. Missing Confounding Data in Marginal Structural Models: A Comparison of Inverse Probability Weighting and Multiple Imputation. *The International Journal of Biostatistics*. 2008;4(1). doi: [doi:10.2202/1557-4679.1106](https://doi.org/10.2202/1557-4679.1106)
24. Silverman BW. *Density estimation for statistics and data analysis*. Routledge, 2018.
25. Ali MS, Groenwold RH, Belitser SV, et al. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. *Journal of Clinical Epidemiology*. 2015;68(2):122–131. doi: <https://doi.org/10.1016/j.jclinepi.2014.08.011>
26. Myers JA, Rassen JA, Gagne JJ, et al. Effects of Adjusting for Instrumental Variables on Bias and Precision of Effect Estimates. *American Journal of Epidemiology*. 2011;174(11):1213–1222. doi: [10.1093/aje/kwr364](https://doi.org/10.1093/aje/kwr364)
27. Pearl J. On a class of bias-amplifying variables that endanger effect estimates. *arXiv preprint arXiv:1203.3503*. 2012.
28. LaRosa JC, He J, Vupputuri S. Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials. *JAMA*. 1999;282(24):2340–2346. doi: [10.1001/jama.282.24.2340](https://doi.org/10.1001/jama.282.24.2340)
29. Law MR, Wald NJ, Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *Bmj*. 2003;326(7404):1423–1438.
30. Simes J, Furberg C, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. *European Heart Journal*. 2002;23(3):207–215. doi: [10.1053/euhj.2001.2775](https://doi.org/10.1053/euhj.2001.2775)
31. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. *Cochrane database of systematic reviews*. 2011(1)
32. Cheung BMY, Lam KSL. Never too old for statin treatment?. *The Lancet*. 2019;393(10170):379–380. doi: [https://doi.org/10.1016/S0140-6736\(18\)32263-3](https://doi.org/10.1016/S0140-6736(18)32263-3)
33. Xiao Y, Abrahamowicz M, Moodie EEM. Accuracy of conventional and marginal structural Cox model estimators: a simulation study. *The International Journal of Biostatistics*. 2010;6(2). doi: [doi:10.2202/1557-4679.1208](https://doi.org/10.2202/1557-4679.1208)
34. Diop A, Sirois C, Guertin JR, et al. Marginal structural models with latent class growth analysis of treatment trajectories: Statins for primary prevention among older adults. *Statistical Methods in Medical Research*. 2023;32(11):2207–2225. PMID: 37750253 doi: [10.1177/09622802231202384](https://doi.org/10.1177/09622802231202384)
35. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. *Statistics in Medicine*. 2007;26(1):20–36. doi: <https://doi.org/10.1002/sim.2739>

Supplementary material for “Evaluation and comparison of covariate balance metrics in studies with time-dependent confounding” by David Adenyo, Jason R Guertin, Bernard Candas, Caroline Sirois and Denis Talbot.

APPENDIX 1 – DETAILED PARAMETERS FOR THE SIMULATION STUDIES.

In this section, we present the parameters used to simulate the data in the different scenarios.

Simulation scenario	Parameter values
Scenario 1 (Base case)	<p>Covariates and exposure at time-point 0: $\delta_0 = -0.05, \alpha_0 = -1.3, \phi_{L_0} = 0.05, \phi_{M_0} = 0.05, \phi_{N_0} = 0.1, \phi_{O_0} = 0.75, \phi_{P_0} = 0.5, \phi_{Q_0} = 0.4, \phi_{T_0} = \phi_{R_0} = \phi_{V_0} = \phi_{Z_0} = 0$</p> <p>Covariates and exposure at time-point 1: $\beta = 0, \gamma_0 = -1, \gamma_1 = -0.5, \gamma_2 = -0.25, \delta_1 = 1.23, \gamma_3 = -0.5,$ $\mu_0 = -1.1, \gamma_4 = -0.75, \alpha_1 = -1.7, \phi_{L_1} = 0.05, \phi_{M_1} = 0.05, \phi_{N_1} = 0.1, \phi_{O_1} = 0.75, \phi_{P_1} = 0.5, \phi_{Q_1} = 0.4, \phi_{T_1} = \phi_{R_1} = \phi_{V_1} = \phi_{Z_1} = 0, \theta = 0.69$</p> <p>Outcome: $\alpha_Y = -4.3, \beta_{L_0} = \beta_{L_1} = 0.5, \beta_{M_0} = \beta_{M_1} = 0.5, \beta_{N_0} = \beta_{N_1} = 0.05, \beta_{O_0} = \beta_{O_1} = 1, \beta_{P_0} = \beta_{P_1} = 1, \beta_{Q_0} = \beta_{Q_1} = 0.2, \beta_{T_0} = \beta_{T_1} = 0, \beta_{R_0} = \beta_{R_1} = 0, \beta_{V_0} = \beta_{V_1} = 0, \beta_{Z_0} = \beta_{Z_1} = 0, \beta_{A_0} = \beta_{A_1} = -0.69$</p>
Scenario 4 (High imbalance, no confounding)	<p>Covariates and exposure at time-point 0: $\delta_0 = -0.05, \alpha_0 = -3.25, \phi_{L_0} = 1, \phi_{M_0} = 1, \phi_{N_0} = 0.1, \phi_{O_0} = 2, \phi_{P_0} = 2, \phi_{Q_0} = 0.4, \phi_{T_0} = \phi_{R_0} = \phi_{V_0} = \phi_{Z_0} = 0$</p> <p>Covariates and exposure at time-point 1: $\beta = 0, \gamma_0 = -1, \gamma_1 = -0.5, \gamma_2 = -0.25, \delta_1 = 1.23, \gamma_3 = -0.5,$ $\mu_0 = -1.1, \gamma_4 = -0.75, \alpha_1 = -2.93, \phi_{L_1} = 1, \phi_{M_1} = 1, \phi_{N_1} = 0.1, \phi_{O_1} = 2, \phi_{P_1} = 2, \phi_{Q_1} = 0.4, \phi_{T_1} = \phi_{R_1} = \phi_{V_1} = \phi_{Z_1} = 0, \theta = 0.69$</p> <p>Outcome: $\alpha_Y = -0.75, \beta_{L_0} = \beta_{L_1} = 0, \beta_{M_0} = \beta_{M_1} = 0, \beta_{N_0} = \beta_{N_1} = 0, \beta_{O_0} = \beta_{O_1} = 0, \beta_{P_0} = \beta_{P_1} = 0, \beta_{Q_0} = \beta_{Q_1} = 0, \beta_{T_0} = \beta_{T_1} = 0, \beta_{R_0} = \beta_{R_1} = 0, \beta_{V_0} = \beta_{V_1} = 0, \beta_{Z_0} = \beta_{Z_1} = 0, \beta_{A_0} = \beta_{A_1} = -0.69$</p>
Scenario 5 (Low imbalance, moderate confounding)	<p>Covariates and exposure at time-point 0: $\delta_0 = -0.05, \alpha_0 = -0.05, \phi_{L_0} = 0.01, \phi_{M_0} = 0.01, \phi_{N_0} = 0.02, \phi_{O_0} = 0.02, \phi_{P_0} = 0.01, \phi_{Q_0} = 0.01, \phi_{T_0} = \phi_{R_0} = \phi_{V_0} = \phi_{Z_0} = 0$</p> <p>Covariates and exposure at time-point 1: $\beta = 0, \gamma_0 = 0, \gamma_1 = 0, \gamma_2 = 0, \delta_1 = -4.5, \gamma_3 = 0,$ $\mu_0 = 0, \gamma_4 = 0, \alpha_1 = -0.2, \phi_{L_1} = 0.01, \phi_{M_1} = 0.01, \phi_{N_1} = 0.02, \phi_{O_1} = 0.02, \phi_{P_1} = 0.01, \phi_{Q_1} = 0.01, \phi_{T_1} = \phi_{R_1} = \phi_{V_1} = \phi_{Z_1} = 0, \theta = 0$</p> <p>Outcome: $\alpha_Y = -20.5, \beta_{L_0} = \beta_{L_1} = 1, \beta_{M_0} = \beta_{M_1} = 1, \beta_{N_0} = \beta_{N_1} = 0.1, \beta_{O_0} = \beta_{O_1} = 2, \beta_{P_0} = \beta_{P_1} = 2, \beta_{Q_0} = \beta_{Q_1} = 0.4, \beta_{T_0} = \beta_{T_1} = 0, \beta_{R_0} = \beta_{R_1} = 0, \beta_{V_0} = \beta_{V_1} = 0, \beta_{Z_0} = \beta_{Z_1} = 0, \beta_{A_0} = \beta_{A_1} = 0$</p>

Simulation scenario	Parameter values
Scenario 6 (High imbalance-high confounding)	<p>Covariates and exposure at time-point 0: $\delta_0 = -0.05, \alpha_0 = -3.25, \phi_{L_0} = 1, \phi_{M_0} = 1, \phi_{N_0} = 0.1, \phi_{O_0} = 2, \phi_{P_0} = 2, \phi_{Q_0} = 0.4, \phi_{T_0} = \phi_{R_0} = \phi_{V_0} = \phi_{Z_0} = 0$</p> <p>Covariates and exposure at time-point 1: $\beta = 0, \gamma_0 = -1, \gamma_1 = -0.5, \gamma_2 = -0.25, \delta_1 = 1.23, \gamma_3 = -0.5, \mu_0 = -1.1, \gamma_4 = -0.75, \alpha_1 = -2.95, \phi_{L_1} = 1, \phi_{M_1} = 1, \phi_{N_1} = 0.1, \phi_{O_1} = 2, \phi_{P_1} = 2, \phi_{Q_1} = 0.4, \phi_{T_1} = \phi_{R_1} = \phi_{V_1} = \phi_{Z_1} = 0, \theta = 0$</p> <p>Outcome: $\alpha_Y = -4.07, \beta_{L_0} = \beta_{L_1} = 0.5, \beta_{M_0} = \beta_{M_1} = 0.5, \beta_{N_0} = \beta_{N_1} = 0.05, \beta_{O_0} = \beta_{O_1} = 1, \beta_{P_0} = \beta_{P_1} = 1, \beta_{Q_0} = \beta_{Q_1} = 0.2, \beta_{T_0} = \beta_{T_1} = 0, \beta_{R_0} = \beta_{R_1} = 0, \beta_{V_0} = \beta_{V_1} = 0, \beta_{Z_0} = \beta_{Z_1} = 0, \beta_{A_0} = \beta_{A_1} = -0.69$</p>
Scenario 7 (Nonlinear outcome)	<p>Covariates and exposure at time-point 0: $\delta_0 = -0.05, \alpha_0 = -1.3, \phi_{L_0} = 0.05, \phi_{M_0} = 0.05, \phi_{N_0} = 0.1, \phi_{O_0} = 0.75, \phi_{P_0} = 0.5, \phi_{Q_0} = 0.4, \phi_{T_0} = \phi_{R_0} = \phi_{V_0} = \phi_{Z_0} = 0$</p> <p>Covariates and exposure at time-point 1: $\beta = 0, \gamma_0 = -1, \gamma_1 = -0.5, \gamma_2 = -0.25, \delta_1 = 1.23, \gamma_3 = -0.5, \mu_0 = -1.1, \gamma_4 = -0.75, \alpha_1 = -1.7, \phi_{L_1} = 0.05, \phi_{M_1} = 0.05, \phi_{N_1} = 0.1, \phi_{O_1} = 0.75, \phi_{P_1} = 0.5, \phi_{Q_1} = 0.4, \phi_{T_1} = \phi_{R_1} = \phi_{V_1} = \phi_{Z_1} = 0, \theta = 0$</p> <p>Outcome: $\alpha_Y = -3.1, \beta_{L_0} = \beta_{L_1} = 0.4, \beta_{M_0} = \beta_{M_1} = 0.03, \beta_{N_0} = \beta_{N_1} = 0.03, \beta_{O_0} = \beta_{O_1} = 0.75, \beta_{P_0} = \beta_{P_1} = 0.75, \beta_{Q_0} = \beta_{Q_1} = 0.2, \beta_{T_0} = \beta_{T_1} = 0.4, \beta_{R_0} = \beta_{R_1} = 0.02, \beta_{V_0} = \beta_{V_1} = 0.04, \beta_{Z_0} = \beta_{Z_1} = 0.5, \beta_{A_0} = \beta_{A_1} = -0.69$</p>
Scenario 8 (Nonlinear outcome and exposure)	<p>Covariates and exposure at time-point 0: $\delta_0 = -0.05, \alpha_0 = -1.14, \phi_{L_0} = 0.05, \phi_{M_0} = 0.05, \phi_{N_0} = 0.1, \phi_{O_0} = 0.5, \phi_{P_0} = 0.25, \phi_{Q_0} = 0.4, \phi_{T_0} = 0.01, \phi_{R_0} = 0.02, \phi_{V_0} = 0.01, \phi_{Z_0} = 0.1$</p> <p>Covariates and exposure at time-point 1: $\beta = 0, \gamma_0 = -1, \gamma_1 = -0.5, \gamma_2 = -0.25, \delta_1 = 1.23, \gamma_3 = -0.5, \mu_0 = -1.08, \gamma_4 = -0.75, \alpha_1 = -1.5, \phi_{L_1} = 0.05, \phi_{M_1} = 0.05, \phi_{N_1} = 0.1, \phi_{O_1} = 0.5, \phi_{P_1} = 0.25, \phi_{Q_1} = 0.4, \phi_{T_1} = 0.01, \phi_{R_1} = 0.02, \phi_{V_1} = 0.01, \phi_{Z_1} = 0.1, \theta = 0.69$</p> <p>Outcome: $\alpha_Y = -3.1, \beta_{L_0} = \beta_{L_1} = 0.4, \beta_{M_0} = \beta_{M_1} = 0.03, \beta_{N_0} = \beta_{N_1} = 0.03, \beta_{O_0} = \beta_{O_1} = 0.75, \beta_{P_0} = \beta_{P_1} = 0.75, \beta_{Q_0} = \beta_{Q_1} = 0.2, \beta_{T_0} = \beta_{T_1} = 0.4, \beta_{R_0} = \beta_{R_1} = 0.02, \beta_{V_0} = \beta_{V_1} = 0.04, \beta_{Z_0} = \beta_{Z_1} = 0.5, \beta_{A_0} = \beta_{A_1} = -0.69$</p>
Scenario 9 (Redundant Covariates)	<p>Covariates and exposure at time-point 0: $\delta_0 = -0.05, \alpha_0 = -0.37, \phi_{L_0} = 0.2, \phi_{M_0} = 0.03, \phi_{N_0} = 0.02, \phi_{O_0} = 0, \phi_{P_0} = 1.5, \phi_{Q_0} = 0.01, \phi_{T_0} = 0.01, \phi_{R_0} = 0.02, \phi_{V_0} = 0, \phi_{Z_0} = 0$</p> <p>Covariates and exposure at time-point 1: $\beta = 0, \gamma_0 = -1, \gamma_1 = -0.5, \gamma_2 = -0.25, \delta_1 = 1.23, \gamma_3 = -0.5, \mu_0 = -1.08, \gamma_4 = -0.75, \alpha_1 = -0.59, \phi_{L_1} = 0.2, \phi_{M_1} = 0.03, \phi_{N_1} = 0.02, \phi_{O_1} = 0, \phi_{P_1} = 1.5, \phi_{Q_1} = 0.01, \phi_{T_1} = 0.01, \phi_{R_1} = 0.02, \phi_{V_1} = 0, \phi_{Z_1} = 0, \theta = 0.69$</p> <p>Outcome: $\alpha_Y = -2, \beta_{L_0} = \beta_{L_1} = 0.4, \beta_{M_0} = \beta_{M_1} = 0.03, \beta_{N_0} = \beta_{N_1} = 0.03, \beta_{O_0} = \beta_{O_1} = 0, \beta_{P_0} = \beta_{P_1} = 0.75, \beta_{Q_0} = \beta_{Q_1} = 0.2, \beta_{T_0} = \beta_{T_1} = 0.4, \beta_{R_0} = \beta_{R_1} = 0.02, \beta_{V_0} = \beta_{V_1} = 0, \beta_{Z_0} = \beta_{Z_1} = 0, \beta_{A_0} = \beta_{A_1} = -0.69$</p>

Simulation scenario	Parameter values
Scenario 10 (Instrumental variables)	<p>Covariates and exposure at time-point 0: $\delta_0 = -0.05, \alpha_0 = -0.4, \phi_{L_0} = 0.2, \phi_{M_0} = 0.03, \phi_{N_0} = 0.02, \phi_{O_0} = 0.5, \phi_{P_0} = 0.25, \phi_{Q_0} = 0.01, \phi_{T_0} = 0.01, \phi_{R_0} = 0.02, \phi_{V_0} = 0.01, \phi_{Z_0} = 0.1$</p> <p>Covariates and exposure at time-point 1: $\beta = 0, \gamma_0 = -1, \gamma_1 = -0.5, \gamma_2 = -0.25, \delta_1 = 1.21, \gamma_3 = -0.5,$ $\mu_0 = -1.08, \gamma_4 = -0.75, \alpha_1 = -0.6, \phi_{L_1} = 0.2, \phi_{M_1} = 0.03, \phi_{N_1} = 0.02, \phi_{O_1} = 0.5, \phi_{P_1} = 0.25, \phi_{Q_1} = 0.01, \phi_{T_1} = 0.01, \phi_{R_1} = 0.02, \phi_{V_1} = 0.01, \phi_{Z_1} = 0.1, \theta = 0.69$</p> <p>Outcome: $\alpha_Y = -2, \beta_{L_0} = \beta_{L_1} = 0.4, \beta_{M_0} = \beta_{M_1} = 0, \beta_{N_0} = \beta_{N_1} = 0.03, \beta_{O_0} = \beta_{O_1} = 0.75, \beta_{P_0} = \beta_{P_1} = 0.75, \beta_{Q_0} = \beta_{Q_1} = 0.2, \beta_{T_0} = \beta_{T_1} = 0.4, \beta_{R_0} = \beta_{R_1} = 0, \beta_{V_0} = \beta_{V_1} = 0.04, \beta_{Z_0} = \beta_{Z_1} = 0.5, \beta_{A_0} = \beta_{A_1} = -0.69$</p>
Base case Scenario with censoring	<p>Censoring indicator at time-point 1: $\mu_1 = -2.7, \mu_{L_0} = 0.04, \mu_{M_0} = 0.05, \mu_{N_0} = 0.02, \mu_{O_0} = 1, \mu_{P_0} = 0.02, \mu_{Q_0} = 0.01, \lambda = 1$</p>

APPENDIX 2 – DETAILED SIMULATION RESULTS FOR SCENARIOS 2 TO 10

In this section, we present the average covariate imbalances across covariates at each time-point and average bias for Scenarios 2 to 10. Averages are taken over 1,000 simulated datasets in the unweighted data and in data weighted according to the five weights.

TABLE 6 Average covariate imbalances in Scenario 2 (Low prevalence of exposure)

	D			SMD			OVL			KS			Bias
Unweighted	1.53	0.07	1.51	0.34	0.02	0.32	0.46	0.37	0.43	0.14	0.02	0.13	0.33
$W_0 \times W_1$	0.08	0.07	0.08	0.03	0.03	0.03	0.40	0.37	0.38	0.02	0.02	0.02	0.02
W_1	1.53	0.05	0.06	0.34	0.02	0.02	0.46	0.37	0.38	0.15	0.02	0.02	0.12
W_0	0.06	0.06	1.52	0.02	0.02	0.32	0.40	0.37	0.43	0.02	0.02	0.14	0.10
$W_0\text{tr}90 \times W_1$	0.69	0.05	0.07	0.15	0.02	0.02	0.42	0.37	0.38	0.07	0.02	0.02	0.04
$W_0 \times W_1\text{tr}90$	0.07	0.05	0.68	0.02	0.02	0.14	0.40	0.37	0.40	0.02	0.02	0.07	0.03
	LD			MHB			CS			GWD			Bias
Unweighted	0.13	0.01	0.12	1.18	0.01	1.11	0.56	0.55	0.55	0.19	0.01	0.18	0.33
$W_0 \times W_1$	0.02	0.02	0.02	0.01	0.01	0.01	0.04	0.03	0.03	0.02	0.02	0.02	0.02
W_1	0.13	0.01	0.01	1.18	0.00	0.00	0.56	0.03	0.03	0.19	0.01	0.01	0.12
W_0	0.01	0.01	0.12	0.00	0.01	1.11	0.04	0.54	0.54	0.01	0.02	0.18	0.10
$W_0\text{tr}90 \times W_1$	0.06	0.02	0.02	0.22	0.00	0.01	0.56	0.03	0.03	0.08	0.02	0.02	0.04
$W_0 \times W_1\text{tr}90$	0.01	0.01	0.06	0.00	0.00	0.21	0.04	0.54	0.54	0.01	0.01	0.08	0.03

TABLE 7 Average covariate imbalances in Scenario 3 (Small sample)

	D			SMD			OVL			KS			Bias
Unweighted	1.45	0.13	1.42	0.33	0.05	0.29	0.42	0.35	0.40	0.15	0.04	0.13	0.29
$W_0 \times W_1$	0.14	0.15	0.14	0.06	0.06	0.05	0.37	0.36	0.36	0.05	0.05	0.05	0.04
W_1	1.45	0.06	0.09	0.33	0.02	0.03	0.42	0.35	0.36	0.15	0.04	0.04	0.11
W_0	0.08	0.17	1.42	0.03	0.07	0.30	0.36	0.35	0.41	0.04	0.05	0.14	0.10
$W_0\text{tr}90 \times W_1$	0.52	0.07	0.11	0.12	0.03	0.04	0.38	0.35	0.36	0.07	0.04	0.04	0.04
$W_0 \times W_1\text{tr}90$	0.10	0.14	0.52	0.04	0.05	0.11	0.37	0.35	0.37	0.04	0.04	0.07	0.04
	LD			MHB			CS			GWD			Bias
Unweighted	0.13	0.03	0.12	1.13	0.03	1.03	0.55	0.54	0.54	0.17	0.03	0.15	0.29
$W_0 \times W_1$	0.04	0.04	0.04	0.03	0.03	0.03	0.08	0.08	0.08	0.04	0.04	0.04	0.04
W_1	0.14	0.03	0.03	1.15	0.01	0.01	0.54	0.09	0.09	0.17	0.02	0.03	0.11
W_0	0.03	0.04	0.13	0.01	0.04	1.05	0.09	0.53	0.53	0.02	0.04	0.15	0.10
$W_0\text{tr}90 \times W_1$	0.06	0.03	0.03	0.16	0.01	0.01	0.52	0.08	0.08	0.07	0.03	0.03	0.04
$W_0 \times W_1\text{tr}90$	0.03	0.03	0.06	0.01	0.02	0.15	0.08	0.49	0.49	0.03	0.03	0.06	0.04

TABLE 8 Average covariate imbalances in Scenario 4 (High imbalance, no confounding)

	D			SMD			OVL			KS			Bias
Unweighted	1.22	0.31	1.25	0.62	0.14	0.68	0.47	0.36	0.48	0.25	0.07	0.28	0.02
$W_0 \times W_1$	0.17	0.16	0.18	0.08	0.07	0.08	0.38	0.37	0.38	0.05	0.05	0.05	0.08
W_1	1.22	0.07	0.10	0.62	0.03	0.04	0.47	0.35	0.36	0.26	0.03	0.03	0.05
W_0	0.09	0.10	1.25	0.04	0.04	0.68	0.36	0.35	0.48	0.03	0.03	0.28	0.04
$W_0\text{tr}90 \times W_1$	0.74	0.08	0.11	0.36	0.03	0.05	0.42	0.35	0.36	0.15	0.03	0.03	0.05
$W_0 \times W_1\text{tr}90$	0.10	0.11	0.77	0.04	0.05	0.41	0.36	0.35	0.42	0.03	0.03	0.17	0.04
	LD			MHB			CS			GWD			Bias
Unweighted	0.22	0.06	0.24	3.16	0.12	3.31	0.79	0.80	0.80	0.31	0.08	0.33	0.02
$W_0 \times W_1$	0.04	0.04	0.04	0.05	0.04	0.05	0.21	0.19	0.19	0.04	0.04	0.05	0.08
W_1	0.22	0.02	0.02	3.19	0.01	0.02	0.79	0.15	0.15	0.31	0.02	0.03	0.05
W_0	0.02	0.02	0.24	0.01	0.02	3.33	0.15	0.79	0.79	0.03	0.03	0.33	0.04
$W_0\text{tr}90 \times W_1$	0.13	0.02	0.02	0.98	0.01	0.02	0.78	0.15	0.15	0.19	0.02	0.03	0.05
$W_0 \times W_1\text{tr}90$	0.02	0.02	0.15	0.02	0.02	1.05	0.15	0.78	0.78	0.03	0.03	0.21	0.04

TABLE 9 Average covariate imbalances in Scenario 5 (Low imbalance, moderate confounding)

	D			SMD			OVL			KS			Bias
Unweighted	0.34	0.04	0.37	0.05	0.02	0.05	0.34	0.33	0.34	0.02	0.01	0.03	0.23
$W_0 \times W_1$	0.00	0.00	0.01	0.00	0.00	0.00	0.33	0.33	0.33	0.01	0.01	0.01	0.05
W_1	0.34	0.00	0.00	0.05	0.00	0.00	0.34	0.33	0.33	0.02	0.01	0.01	0.08
W_0	0.00	0.04	0.37	0.00	0.02	0.05	0.33	0.33	0.34	0.01	0.01	0.03	0.15
$W_0\text{tr}90 \times W_1$	0.05	0.00	0.00	0.01	0.00	0.00	0.33	0.33	0.33	0.01	0.01	0.01	0.05
$W_0 \times W_1\text{tr}90$	0.00	0.01	0.05	0.00	0.00	0.01	0.33	0.33	0.33	0.01	0.01	0.01	0.05
	LD			MHB			CS			GWD			Bias
Unweighted	0.02	0.01	0.02	0.04	0.00	0.04	0.11	0.12	0.12	0.03	0.01	0.03	0.23
$W_0 \times W_1$	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05
W_1	0.02	0.00	0.00	0.04	0.00	0.00	0.11	0.00	0.00	0.03	0.00	0.00	0.08
W_0	0.00	0.01	0.02	0.00	0.00	0.04	0.00	0.12	0.12	0.00	0.01	0.03	0.15
$W_0\text{tr}90 \times W_1$	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.00	0.00	0.01	0.00	0.00	0.05
$W_0 \times W_1\text{tr}90$	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.12	0.12	0.00	0.00	0.01	0.05

TABLE 10 Average covariate imbalances in Scenario 6 (High imbalance-high confounding)

	D			SMD			OVL			KS			Bias
Unweighted	1.22	0.31	1.25	0.62	0.14	0.68	0.47	0.36	0.48	0.25	0.07	0.28	1.81
$W_0 \times W_1$	0.17	0.17	0.18	0.08	0.07	0.08	0.38	0.37	0.38	0.05	0.05	0.05	0.04
W_1	1.22	0.07	0.10	0.62	0.03	0.04	0.47	0.35	0.36	0.26	0.03	0.03	0.30
W_0	0.09	0.10	1.25	0.04	0.04	0.68	0.36	0.35	0.48	0.03	0.03	0.28	0.44
$W_0\text{tr}90 \times W_1$	0.74	0.08	0.11	0.36	0.03	0.05	0.42	0.35	0.36	0.15	0.03	0.03	0.12
$W_0 \times W_1\text{tr}90$	0.10	0.11	0.77	0.04	0.05	0.41	0.36	0.35	0.42	0.03	0.03	0.17	0.20
	LD			MHB			CS			GWD			Bias
Unweighted	0.22	0.06	0.24	3.16	0.12	3.31	0.79	0.80	0.80	0.31	0.08	0.33	1.81
$W_0 \times W_1$	0.04	0.04	0.04	0.05	0.05	0.05	0.21	0.19	0.19	0.04	0.04	0.05	0.04
W_1	0.22	0.02	0.02	3.19	0.01	0.02	0.79	0.15	0.15	0.31	0.02	0.03	0.30
W_0	0.02	0.02	0.24	0.01	0.02	3.33	0.15	0.79	0.79	0.03	0.03	0.33	0.44
$W_0\text{tr}90 \times W_1$	0.13	0.02	0.02	0.98	0.01	0.02	0.78	0.15	0.15	0.19	0.02	0.03	0.12
$W_0 \times W_1\text{tr}90$	0.02	0.02	0.15	0.02	0.02	1.05	0.15	0.78	0.78	0.03	0.03	0.21	0.20

TABLE 11 Average covariate imbalances in Scenario 7 (Nonlinear outcome)

	D			SMD			OVL			KS			Bias
Unweighted	1.28	0.07	1.26	0.30	0.02	0.26	0.39	0.32	0.37	0.12	0.02	0.11	0.37
$W_0 \times W_1$	0.05	0.05	0.05	0.02	0.02	0.02	0.34	0.32	0.33	0.02	0.02	0.02	0.02
W_1	1.28	0.02	0.03	0.30	0.01	0.01	0.39	0.32	0.33	0.13	0.01	0.01	0.13
W_0	0.03	0.06	1.26	0.01	0.02	0.26	0.34	0.32	0.38	0.01	0.02	0.11	0.12
$W_0\text{tr}90 \times W_1$	0.45	0.03	0.04	0.10	0.01	0.01	0.35	0.32	0.33	0.05	0.01	0.01	0.03
$W_0 \times W_1\text{tr}90$	0.04	0.05	0.44	0.01	0.02	0.09	0.34	0.32	0.34	0.01	0.01	0.04	0.02
	LD			MHB			CS			GWD			Bias
Unweighted	0.11	0.01	0.10	1.09	0.01	1.02	0.54	0.53	0.53	0.14	0.01	0.12	0.37
$W_0 \times W_1$	0.01	0.01	0.01	0.01	0.01	0.01	0.04	0.04	0.04	0.01	0.01	0.01	0.02
W_1	0.11	0.01	0.01	1.10	0.00	0.00	0.54	0.04	0.04	0.14	0.01	0.01	0.13
W_0	0.01	0.01	0.10	0.00	0.01	1.02	0.05	0.52	0.52	0.01	0.01	0.12	0.12
$W_0\text{tr}90 \times W_1$	0.04	0.01	0.01	0.14	0.00	0.00	0.54	0.04	0.04	0.05	0.01	0.01	0.03
$W_0 \times W_1\text{tr}90$	0.01	0.01	0.03	0.00	0.01	0.13	0.04	0.52	0.52	0.01	0.01	0.04	0.02

TABLE 12 Average covariate imbalances in Scenario 8 (Nonlinear outcome and exposure)

	D			SMD			OVL			KS			Bias
Unweighted	1.34	0.09	1.30	0.28	0.02	0.24	0.38	0.32	0.36	0.11	0.02	0.10	0.32
$W_0 \times W_1$	0.06	0.05	0.06	0.02	0.02	0.02	0.33	0.32	0.32	0.02	0.02	0.02	0.01
W_1	1.34	0.02	0.05	0.28	0.01	0.01	0.38	0.32	0.32	0.11	0.01	0.01	0.12
W_0	0.05	0.06	1.30	0.01	0.02	0.24	0.33	0.32	0.36	0.01	0.02	0.10	0.11
$W_0\text{tr}90 \times W_1$	0.48	0.03	0.05	0.10	0.01	0.02	0.34	0.32	0.32	0.04	0.01	0.01	0.03
$W_0 \times W_1\text{tr}90$	0.05	0.05	0.47	0.02	0.02	0.09	0.33	0.32	0.33	0.01	0.01	0.04	0.02
	LD			MHB			CS			GWD			Bias
Unweighted	0.10	0.01	0.09	1.09	0.01	1.03	0.54	0.53	0.53	0.13	0.01	0.11	0.32
$W_0 \times W_1$	0.01	0.01	0.01	0.01	0.01	0.01	0.04	0.04	0.04	0.01	0.01	0.01	0.01
W_1	0.10	0.01	0.01	1.09	0.00	0.01	0.54	0.04	0.04	0.13	0.01	0.01	0.12
W_0	0.01	0.01	0.09	0.01	0.01	1.03	0.03	0.53	0.53	0.01	0.01	0.11	0.11
$W_0\text{tr}90 \times W_1$	0.04	0.01	0.01	0.14	0.00	0.01	0.53	0.03	0.03	0.05	0.01	0.01	0.03
$W_0 \times W_1\text{tr}90$	0.01	0.01	0.03	0.01	0.01	0.13	0.03	0.52	0.52	0.01	0.01	0.04	0.02

TABLE 13 Average covariate imbalances in Scenario 9 (Redundant Covariates)

	D			SMD			OVL			KS			Bias
Unweighted	0.36	0.04	0.32	0.18	0.02	0.14	0.26	0.23	0.25	0.07	0.02	0.06	0.12
$W_0 \times W_1$	0.02	0.02	0.02	0.01	0.01	0.01	0.24	0.23	0.23	0.01	0.01	0.01	0.01
W_1	0.36	0.01	0.01	0.18	0.00	0.00	0.26	0.23	0.23	0.07	0.01	0.01	0.05
W_0	0.01	0.04	0.32	0.00	0.02	0.14	0.24	0.23	0.25	0.01	0.02	0.06	0.05
$W_0\text{tr}90 \times W_1$	0.08	0.01	0.01	0.05	0.01	0.01	0.24	0.22	0.23	0.03	0.01	0.01	0.01
$W_0 \times W_1\text{tr}90$	0.01	0.02	0.08	0.01	0.01	0.04	0.24	0.23	0.23	0.01	0.01	0.02	0.01
	LD			MHB			CS			GWD			Bias
Unweighted	0.06	0.01	0.05	0.40	0.00	0.33	0.32	0.29	0.29	0.09	0.01	0.07	0.12
$W_0 \times W_1$	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01
W_1	0.06	0.00	0.00	0.40	0.00	0.00	0.32	0.01	0.01	0.09	0.01	0.01	0.05
W_0	0.00	0.01	0.05	0.00	0.00	0.33	0.01	0.28	0.28	0.01	0.01	0.07	0.05
$W_0\text{tr}90 \times W_1$	0.02	0.01	0.01	0.04	0.00	0.00	0.32	0.00	0.00	0.03	0.01	0.01	0.01
$W_0 \times W_1\text{tr}90$	0.01	0.01	0.02	0.00	0.00	0.03	0.00	0.28	0.28	0.01	0.01	0.02	0.01

TABLE 14 Average covariate imbalances in Scenario 10 (Instrumental variables)

	D			SMD			OVL			KS			Bias
Unweighted	0.58	0.05	0.55	0.23	0.02	0.18	0.41	0.36	0.40	0.11	0.01	0.09	0.21
$W_0 \times W_1$	0.04	0.02	0.04	0.01	0.01	0.01	0.37	0.36	0.37	0.01	0.01	0.01	0.01
W_1	0.58	0.01	0.04	0.23	0.00	0.01	0.41	0.36	0.37	0.11	0.01	0.01	0.09
W_0	0.03	0.04	0.55	0.01	0.02	0.18	0.37	0.36	0.40	0.01	0.01	0.09	0.08
$W_0\text{tr}90 \times W_1$	0.13	0.02	0.04	0.04	0.01	0.01	0.37	0.36	0.37	0.02	0.01	0.01	0.01
$W_0 \times W_1\text{tr}90$	0.04	0.02	0.13	0.01	0.01	0.04	0.37	0.36	0.37	0.01	0.01	0.02	0.01
	LD			MHB			CS			GWD			Bias
Unweighted	0.09	0.01	0.07	0.25	0.00	0.16	0.28	0.23	0.23	0.10	0.01	0.08	0.21
$W_0 \times W_1$	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01	0.01	0.01
W_1	0.09	0.00	0.00	0.25	0.00	0.00	0.28	0.02	0.02	0.10	0.01	0.01	0.09
W_0	0.00	0.01	0.07	0.00	0.00	0.16	0.01	0.22	0.22	0.01	0.01	0.08	0.08
$W_0\text{tr}90 \times W_1$	0.02	0.00	0.00	0.01	0.00	0.00	0.26	0.01	0.01	0.02	0.01	0.01	0.01
$W_0 \times W_1\text{tr}90$	0.00	0.00	0.02	0.00	0.00	0.01	0.00	0.22	0.22	0.01	0.01	0.02	0.01

APPENDIX 3 – CONNECTION BETWEEN THE STANDARDIZED MEAN DIFFERENCE AND THE MAHALANOBIS BALANCE

In this section we present a mathematical connection between the standardized mean difference and the Mahalanobis balance on which is based our proposed threshold for the Mahalanobis balance. To simplify the presentation, we consider two uncorrelated covariates.

Let $X_T = (X_{1T}, X_{2T})^\top$ be the vector of covariates in treated subjects, with $X_{1T} = (x_{11T}, x_{12T}, \dots, x_{1n_1T})$, $X_{2T} = (x_{21T}, x_{22T}, \dots, x_{2n_1T})$ and n_1 is the number of treated subjects. We also note $X_C = (X_{1C}, X_{2C})^\top$ the vector of covariates in the untreated subjects, with $X_{1C} = (x_{11C}, x_{12C}, \dots, x_{1n_2C})$, $X_{2C} = (x_{21C}, x_{22C}, \dots, x_{2n_2C})$ and n_2 the number of untreated subjects. The Mahalanobis balance is given by:

$$MHB = (\bar{X}_T - \bar{X}_C)^\top \Sigma^{-1} (\bar{X}_T - \bar{X}_C), \text{ where}$$

$\bar{X}_T = (\bar{X}_{1T}, \bar{X}_{2T})^\top$, $\bar{X}_C = (\bar{X}_{1C}, \bar{X}_{2C})^\top$ are the sample averages and

$$\Sigma = \frac{\text{var}(X_T) + \text{var}(X_C)}{2}.$$

We have

$$\Sigma = \begin{pmatrix} \frac{\text{var}(X_{1T}) + \text{var}(X_{1C})}{2} & \frac{\text{cov}(X_{1T}, X_{2T}) + \text{cov}(X_{1C}, X_{2C})}{2} \\ \frac{\text{cov}(X_{1T}, X_{2T}) + \text{cov}(X_{1C}, X_{2C})}{2} & \frac{\text{var}(X_{2T}) + \text{var}(X_{2C})}{2} \end{pmatrix},$$

$$\Sigma^{-1} = \frac{1}{A} \begin{pmatrix} \frac{\text{var}(X_{2T}) + \text{var}(X_{2C})}{2} & -\frac{\text{cov}(X_{1T}, X_{2T}) + \text{cov}(X_{1C}, X_{2C})}{2} \\ -\frac{\text{cov}(X_{1T}, X_{2T}) + \text{cov}(X_{1C}, X_{2C})}{2} & \frac{\text{var}(X_{1T}) + \text{var}(X_{1C})}{2} \end{pmatrix}, \text{ where}$$

$$A = \frac{[\text{var}(X_{1T}) + \text{var}(X_{1C})][\text{var}(X_{2T}) + \text{var}(X_{2C})]}{2^2} - \left(\frac{\text{cov}(X_{1T}, X_{2T}) + \text{cov}(X_{1C}, X_{2C})}{2} \right)^2.$$

As such,

$$\begin{aligned} MHB &= \frac{1}{A} (\bar{X}_{1T} - \bar{X}_{1C}, \bar{X}_{2T} - \bar{X}_{2C}) \\ &\quad \times \begin{pmatrix} \frac{\text{var}(X_{2T}) + \text{var}(X_{2C})}{2} & -\frac{\text{cov}(X_{1T}, X_{2T}) + \text{cov}(X_{1C}, X_{2C})}{2} \\ -\frac{\text{cov}(X_{1T}, X_{2T}) + \text{cov}(X_{1C}, X_{2C})}{2} & \frac{\text{var}(X_{1T}) + \text{var}(X_{1C})}{2} \end{pmatrix} \begin{pmatrix} \bar{X}_{1T} - \bar{X}_{1C} \\ \bar{X}_{2T} - \bar{X}_{2C} \end{pmatrix} \\ &= \frac{1}{A} \left[\frac{(\bar{X}_{1T} - \bar{X}_{1C})^2 \text{var}(X_{2T}) + (\bar{X}_{1T} - \bar{X}_{1C})^2 \text{var}(X_{2C})}{2} - \frac{(\bar{X}_{2T} - \bar{X}_{2C})(\bar{X}_{1T} - \bar{X}_{1C}) \text{cov}(X_{1T}, X_{2T})}{2} \right. \\ &\quad - \frac{(\bar{X}_{2T} - \bar{X}_{2C})(\bar{X}_{1T} - \bar{X}_{1C}) \text{cov}(X_{1C}, X_{2C})}{2} - \frac{(\bar{X}_{1T} - \bar{X}_{1C})(\bar{X}_{2T} - \bar{X}_{2C}) \text{cov}(X_{1T}, X_{2T})}{2} \\ &\quad \left. - \frac{(\bar{X}_{1T} - \bar{X}_{1C})(\bar{X}_{2T} - \bar{X}_{2C}) \text{cov}(X_{1C}, X_{2C})}{2} + \frac{(\bar{X}_{2T} - \bar{X}_{2C})^2 \text{var}(X_{1T})}{2} + \frac{(\bar{X}_{2T} - \bar{X}_{2C})^2 \text{var}(X_{1C})}{2} \right] \\ &= \frac{1}{A} \left[\frac{(\bar{X}_{1T} - \bar{X}_{1C})^2 [\text{var}(X_{2T}) + \text{var}(X_{2C})]}{2} - 2 \times \frac{(\bar{X}_{2T} - \bar{X}_{2C})(\bar{X}_{1T} - \bar{X}_{1C}) [\text{cov}(X_{1T}, X_{2T}) + \text{cov}(X_{1C}, X_{2C})]}{2} \right. \\ &\quad \left. + \frac{(\bar{X}_{2T} - \bar{X}_{2C})^2 [\text{var}(X_{1T}) + \text{var}(X_{1C})]}{2} \right] \end{aligned}$$

Since X_1 and X_2 are uncorrelated, $\text{cov}(X_{1T}, X_{2T}) = \text{cov}(X_{1C}, X_{2C}) = 0$ and we have

$$MHB = \frac{1}{B} \left[\frac{(\bar{X}_{1T} - \bar{X}_{1C})^2 [\text{var}(X_{2T}) + \text{var}(X_{2C})]}{2} + \frac{(\bar{X}_{2T} - \bar{X}_{2C})^2 [\text{var}(X_{1T}) + \text{var}(X_{1C})]}{2} \right], \text{ where}$$

$$B = \frac{[\text{var}(X_{1T}) + \text{var}(X_{1C})][\text{var}(X_{2T}) + \text{var}(X_{2C})]}{2^2}.$$

As a result,

$$\begin{aligned}
 MHB &= \frac{2(\bar{X}_{1T} - \bar{X}_{1C})^2 [\text{var}(X_{2T}) + \text{var}(X_{2C})]}{[\text{var}(X_{1T}) + \text{var}(X_{1C})][\text{var}(X_{2T}) + \text{var}(X_{2C})]} + \frac{2(\bar{X}_{2T} - \bar{X}_{2C})^2 [\text{var}(X_{1T}) + \text{var}(X_{1C})]}{[\text{var}(X_{1T}) + \text{var}(X_{1C})][\text{var}(X_{2T}) + \text{var}(X_{2C})]} \\
 &= \frac{2(\bar{X}_{1T} - \bar{X}_{1C})^2}{\text{var}(X_{1T}) + \text{var}(X_{1C})} + \frac{2(\bar{X}_{2T} - \bar{X}_{2C})^2}{\text{var}(X_{2T}) + \text{var}(X_{2C})} \\
 &= \frac{(\bar{X}_{1T} - \bar{X}_{1C})^2}{\frac{\text{var}(X_{1T}) + \text{var}(X_{1C})}{2}} + \frac{(\bar{X}_{2T} - \bar{X}_{2C})^2}{\frac{\text{var}(X_{2T}) + \text{var}(X_{2C})}{2}}.
 \end{aligned}$$

This correspond to the sum of the squared standardized mean differences of the covariates. Consequently, the commonly used threshold of 0.1 for each covariate for the standardized mean difference corresponds to

$$\frac{(\bar{X}_{1T} - \bar{X}_{1C})^2}{\frac{\text{var}(X_{1T}) + \text{var}(X_{1C})}{2}} + \frac{(\bar{X}_{2T} - \bar{X}_{2C})^2}{\frac{\text{var}(X_{2T}) + \text{var}(X_{2C})}{2}} \leq (0.1)^2 + (0.1)^2 = 0.02$$

according to the MHB. Similarly, when p uncorrelated covariates are considered, the corresponding threshold for the MHB is $p \times 0.01$.

APPENDIX 4 – DISTRIBUTIONS OF THE PROPENSITY SCORES IN THE DIFFERENT SIMULATION SCENARIOS

In this section, we provide figures that depict the distributions of the propensity score in each treatment group in a single simulated dataset for each of the simulation scenarios. The red curve corresponds to the treated group and the blue curve to the untreated. Odd panels correspond to the distribution at $t = 0$ and even panels to the distribution at $t = 1$. The first row (panels 1-2) correspond to unweighted data, the second (panels 3-4) to data weighted by $W_0 \times W_1$, the third (panels 5-6) to data weighted by W_1 only, the fourth (panels 7-8) to data weighted according to W_0 only, the fifth (panels 9-10) to the product of W_0 truncated at the 90th percentile with W_1 and the last row (panels 11-12) to the product of W_0 with W_1 truncated at the 90th percentile




FIGURE 3 Distribution of the propensity score in Scenario 2 (Low prevalence of exposure).




FIGURE 4 Distribution of the propensity score in Scenario 3 (Small sample).




FIGURE 5 Distribution of the propensity score in Scenario 4 (High imbalance, no confounding).




FIGURE 6 Distribution of the propensity score in Scenario 5 (Low imbalance, moderate confounding).




FIGURE 7 Distribution of the propensity score in Scenario 6 (High imbalance-high confounding).




FIGURE 8 Distribution of the propensity score in Scenario 7 (Nonlinear outcome).




FIGURE 9 Distribution of the propensity score in Scenario 8 (Nonlinear outcome and exposure).




FIGURE 10 Distribution of the propensity score in Scenario 9 (Redundant Covariates).




FIGURE 11 Distribution of the propensity score in Scenario 10 (Instrumental variables).




FIGURE 12 Distribution of the propensity score in the base case scenario with censoring